feel well live long corporate responsibility report gsk corporate responsibility report approach report home search print forward return use navigation tool right report report available click icon search print report section name section arrow content table underlined link view additional information online report datum datum relate worldwide operation calendar year state datum environment health safety section report performance annually report support reference independently assure sgs information commitment open information online www gskcom approach external assurance provide transparent business activity information corporate responsibility governance management section include annual report brand name appear italic report year restructure report trademark own andor license gsk core theme reflect welcome feedback associate company issue important information report report standard responsible sustainable business growth happy discuss question base report global reporting reflect issue commonly cover initiative gri guideline produce gri raise stakeholder contact csrcontactgskcom index element guideline cover report aid comparison company report join global compact provide index report line global compact expectationsgsk corporate responsibility report approach content content approach people community planet chairman introduction performance introduction waste ceo create value work gsk feature bring carbon minimising use responsible business engage employee science london supply chain material source develop employee olympic operation environmental paralympic game stewardship diversity gsk propellant pulse environmental health safety employee volunteer feature understand governance community impact investment product compliance water performance health water operation external assurance introduction develop country research europe development usa behaviour improve access hivaids healthcare global viiv healthcare introduction clinical research challenge research development ethical conduct patient safety develop country governance management increase access prevent bribery supply chain increase availability community investment corruption supply feature marketing product distribution process introduction stakeholder engagement approach malaria feature change supplier standard approach performance improve affordability way incentivise performance value prevent disease sale team usa security supply raise awareness publishing payment supplier diversity advocacy healthcare professional public policy future plan publish grant patient advocacy donation trade industry training awareness association monitor public policy activity compliance political contribution datum privacy lobbying expenditure research practice patient advocacy animal research human right gsk corporate responsibility report approach chairman gsk believe year good progress role chairman board corporate operating responsible responsibility committee acutely aware ethical way essential pressure challenge face company receive regular report address success business year particularly pleased continued examine commitment improve global access policy operation ensure medicine include agreement supply large quantity approach corporate vaccine protect rotavirus gastroenteritis pneumococcal disease pneumonia responsibility support delivery meningitis poor country world business strategy fraction western price company substantive progress area environmental consistent value sustainability support community operate progress leadership sir andrew executive team board continue support constructively challenge thinking action operate responsible valuesbased business sir andrew witty leave sir christopher gent right sir christopher gent chairmangsk corporate responsibility report approach ceo threeandahalf year ago set record demonstrate succeed demonstrate make significant increase sale return shareholder progress improve return productivity fundamentally change gsk significant progress research development see productivity translate real filing create different type company approval medicine approve remain committed operating transparency ready file include deliver sustainable financial responsibility year multiple new mek inhibitor melanoma new fourvalent advance agenda ensure behaviour performance provide share flu vaccine action meet exceed expectation value patient consumer society reflect report cusp create world government structure area health people malaria vaccine see firsthand devastating community behaviour planet impact disease africa live year october latestage key priority continue align trial confirm promise see far show commercial success form new partnership vaccine reduce risk malaria half tackle healthcare need people develop african child aged month reiterate country particularly pertinent vaccine commitment price vaccine level cover tackle pneumococcal disease great example cost generate small return partnership difference early plough research generation gsk begin supply pneumococcal vaccine kenya malaria medicine vaccine innovative financing mechanism know advance market commitment year reach agreement principle large fund design single vaccine government resolve longstanding dramatically increase sustainable access legal issue sale marketing practice vaccine baby africa settlement billion know difficult necessary step resolve multiple longstanding success build midyear announce matter reflect company today new pricing structure vaccine diarrhoeal disease offer gavi alliance vaccine fraction cost develop western market million child live world poor country set receive save countless life future importantly offer sustainable long term recoup cost good manufacture continue gsk corporate responsibility report approach ceo ongoing strategy continue possible effort fundamentally change procedure compliance employee invest people community marketing sell particularly usa underpin longterm sustainability business ensure operate high standard create right internal external condition integrity conduct business openly support strategy company mindful transparently continue innovate potential pressure employee face give current respond expectation stakeholder global political economic environment despite new compensation system reward sale challenge remain committed offer representative usa quality service employee range learn opportunity tailor sale volume example development volunteering programme pulse programme example give employee chance progress implement join nonprofit nongovernmental organisation environmental strategy revise set sixmonth placement pulse ambitious goal entire value chain raw volunteer delight material product disposal need work way nearly employee country serve enable business growth protect natural pulse volunteer scheme begin resource future example carbon footprint derive propellant patient change right use inhaler eliminate cfc gas business lay foundation future success product substantially reduce inhaler emission come long way mean million tonne equivalent achieve aspire continue tonne today review plan commitment area look establish longterm goal sir andrew witty hear patient visit hospital uganda target support meaningful measurement demonstrate commitment responsible valuesbase business continue restless challenge ask sir andrew witty chief executive officergsk corporate responsibility report approach sciencele global healthcare gsk primary area business pharmaceutical turnover region vaccine consumer healthcare company innovative product million pharmaceutical business develop make usa available medicine treat range infectious europe people world chronic disease portfolio emerge market asia pacific establish brand new innovative patent product develop japan manufacture way protect medicine total vaccine business large world contribute directly produce paediatric adult vaccine range health wellbee patient infectious disease product use component single vaccine help provide employee region consumer indirectly protection multiple disease society economy consumer healthcare business market usa europe range categoryleade consumer health product merge market area oral health nutrition wellness asia pacific skin health japan business sustain investment total spend billion search develop new medicine vaccine innovative consumer product annual report read business strategy performance find lie loe ntt detail corporate governance risk management annual report shareholder annual report onlinegsk corporate responsibility report approach create value place great importance innovation employee positive impact contribution make people live key motivator achieve new medicine healthcare product need working gsk achieve believe business people globe address illness wellcontrolle treat time diverse balanced portfolio play great role scientific research continuously uncover new pharmaceutical vaccine consumer healthcare product provide range product tackle social economic understanding disease process technology grow business change environmental challenge element present opportunity shape business intend provide broadly investigate develop new improved treatment source sale growth great resilience face create value apply science technology market challenge discover develop produce distribute medicine develop new partnership approach vaccine consumer healthcare product adopt mindset innovative openminde access flexible value new different perspective work research charity academia company actively seek new way deliver healthcare nongovernmental organisation make product available affordable flexible intellectual property people need live knowhow stimulate progress search society expect right thing new treatment good business increase consultation patient effort expand access product payer ensure develop medicine healthcare lead industry adopt flexible approach pricing system value reward medicine vaccine base countrys wealth ability pay result significant approach responsible business reduction price increase demand responsible business grow create product emerge economy represent good value shareholder society strategy outcome patient government shareholder design maximise performance commit western market develop new reimbursement operating responsibility transparency strong approach medicine agree riskshare value people central business success arrangement payer report outlined progress different theme reflect issue important responsible sustainable business growth fundamentally change business culture help grow innovate improve review plan commitment performance affect way business way area plan establish target key work relationship employee performance indicatorsgsk corporate responsibility report approach responsible business health people communitie investment infrastructure respect people support employee innovative pricing work stakeholder reach potential positive difference medicine vaccine consumer product community operate available people need possible economic contribution investment education regardless live ability pay programme partnership planet behaviour commit minimise environmental building strong valuesbase culture impact value chain lifecycle recognise need open product set ambitious goal reduce carbon challenge face action footprint water waste back robust policy strong compliance process expect standard supplier contractor business partnersgsk corporate responsibility report health content introduction develop country research europe development usa improve people health improve access hivaids healthcare global viiv healthcare wellbee regardless challenge research development develop country live ability pay increase access increase availability community investment feature approach malaria improve affordability prevent disease raise awareness advocacy future plan click arrow section improve access healthcare societys press social challengesgsk corporate responsibility report health introduction want product progress available accessible affordable invest billion global cofounde significant deliver vaccine people need launch new commitment intellectual use develop country possible aim medicine expect report property wipo research new million dose latestage asset end coalition stimulate research kenya ethiopia generate return need disease develop world country africa introduce sustain business invest result ongoing phase iii gsk pneumococcal vaccine research study malaria vaccine begin project open synflorix innovative candidate rtss show able lab tre canto disease financing mechanism reduce risk malaria half develop world seven new commitment supply understand recognise barrier african child aged month approve million dose gsk anti obstacle path well health oneyear period invest million diarrhoeal vaccine rotarix commit find new innovative way vaccination partnership amref care reduction western market price tackle work partnership listen new commitment support international save child prepare change way business create value society business research effort usa europe support training frontline patient assistance program shareholder tackle antimicrobial resistance healthcare worker provide gsk medicine develop country vaccine worth million outline global approach contribution help create new coalition lead expand work value cost go detail work develop world health organization healthstore foundation improve viiv healthcare licensee supply country challenge increase access control eliminate healthcare rural slum area million tablet healthcare particularly difficult access neglect tropical rwanda kenya establish version epivir combivir issue develop world disease network nurse runclinic set lowincome develop include example work develop country extend albendazole donation new target health post country subsaharan africa enable deworme schoolage stagger sevenyear period child endemic country gsk corporate responsibility report health research development important contribution launch new medicine benlysta significant partnership address neglect treatment systemic lupus erythematosus horizant tropical disease ntd main area collaboration improve health treatment moderatetosevere restless leg include research improve drug discovery research development new syndrome trobalt adjunctive treatment partial biotechnology identify patient safety issue onset seizure start critical twoyear research rare disease sign seven new treatment vaccine consumer period pipeline expect deliver phase iii collaboration give external healthcare product datum readout asset end discovery partnership complement internal discovery unit date positive readout support progression focus product contribute society registration asset disease include fund basic medical research conduct outside address patient need advance science type diabete chronic obstructive pulmonary disease gsk increase understand human body offer good opportunity discover new medicine copd asthma hepatitis melanoma malaria impact disease type research frequently generate commercial return foundation future advance diagnosis discovery performance unit dpus help successful long term need treatment prevention disease improve productivity small investment make pipeline lead new entrepreneurial multidisciplinary team responsible focus find good science medicine value patient discover develop potential new medicine lead creation discovery partnership pay treatment medicine vision process specialist area develop threeyear business academia dpac programme dpac new approach ensure voice customer integrate plan pitch funding project aims establish truly integrate partnership medicine development strategy optimise payer discovery investment board dib academic group undertake early drug discovery patient prescriber need complete majority threeyear progress review translate innovative research medicine invest billion dpus decision benefit patient expenditure pharmaceutical number shape project continue dpac engage nearly academic institute remainder vaccine consumer healthcare research proposal new dpus country world new area emerge pipeline asset latestage vaccine business collaboration external way work future remain flexible development candidate vaccine partner ongoing prophylactic landscape change development approximately onethird target therapeutic vaccine disease particularly prevalent develop right organisation form alliance read dpus medicine world read pipeline progress external group accelerate discovery new vaccine pipeline progress approval annual report medicine vaccine share scientific annual report website understanding ultimately improve patient caregsk corporate responsibility report health case study research development focus patient tackle antimicrobial resistance guide research essential understand antibiotic cornerstone modern medicine barda group office assistant patient need focus patient programme effectively treat common infection secretary preparedness response bring patient gsk site speak directly ensure patient undergo surgery department health human service team healthcare need help immunocompromise example chemotherapy support introduction generating antibiotic well medicine inspire employee hiv transplantation protect infection incentive gain act house help improve patient live gsk lead researcher supplier representative june believe effective antibiotic year antibiotic meaningful step address barrier host patient insight seminar site augmentin remain use world today research development approval new antibiotic theme strengthen patient voice year launch gsk bring people november gsk welcome european include gsk employee healthcare professional past year see increase commission action plan rise threat patient patient advocacy group representative resistance infectious bacteria antibiotic antimicrobial resistance promote discuss range topic include epilepsy ovarian time decline antibiotic research new collaborative research develop new antibiotic cancer asthma immune thrombocytopenia diversity class antibiotic develop launch counter grow threat resistant bacteria clinical trial acute lung injury plasmodium vivax year european centre disease share european commission view public malaria fabry disease crohns disease soft tissue prevention estimate europe people die private collaboration share information sarcoma copd provide recording resistant infection type bacteria funding offer good way forward seminar dedicated area intranet enable commit work innovative medicine employee learn benefit discussion discovery development new antibiotic initiative imi antibiotic programme take year significant investment new team gsk look research partner antibiotic license generally area patient fail respond exist treatment limit commercial return need encourage believe approach need continued research investment support innovation area example investment research new antibiotic product gsk pharmaceutical company commercially viable encourage active antibiotic programme commit guarantee financial agreement success support effort tackle antimicrobial resistance believe regulatory approach reflect september gsk biomedical advanced unique challenge develop treatment multi research development authority barda drug resistant infection urgently need usa agree million contract support development gsk potential new antibiotic hospital gram negative biothreat pathogen european centre disease prevention european medicine agency joint technical report bacterial challenge time react gsk corporate responsibility report health improve access healthcare global challenge improve access healthcare complex factor hamper access believe right thing know medicine develop country poverty single approach contribute business success society press big barrier country people strive meet societys healthcare need social challenge food clean water access function build trust business helps safeguard health system medicine prevalent disease licence operate long term lack limited commercial return year million people die curable improve access healthcare emerge economy neglect disease unify registration preventable infectious disease suffer unnecessary ill help build business increasingly system medicine make process costly health access basic healthcare commercially important market brazil china complex individual authority sufficient service include essential medicine vaccine india indonesia russia past majority capacity numerous product registration cost healthcare barrier access patient revenue country come sell developed develop world despite develop country distribution network medicine vaccine higherincome sector huge medical advance condition medicine weak lack basic infrastructure society achieve sustainable growth need treatment exist need improved hospital clinic healthcare professional barrier highincome sector increase access compound lack political action affordability patient lowerincome level problem affect individual community result inadequate funding healthcare country mean ensure right world acute develop system middleincome country health system product right price right place country particularly world develop develop difference income level country ldc possible work partnership company prevent access problem excuse government international agency academic institution access medicine index inaction indicate action need patient group ngo community provide gsk rank access medicine atm want help improve health business expertise resource medicine vaccine improve index publish second time index activity skill resource act catalyst healthcare infrastructure availability produce atm foundation provide wide change industry society strategy medicine vaccine work independent assessment company effort focus difference achieve patient improve access medicine particular improve affordability availability prevention approach reflect different need market support vulnerable health system please progress recognise vary significantly depend poverty focus conduct encourage investment know income level coverage quality healthcare achieve continue consider recommendation infrastructure political commitment resource atm index carefully review approach work open manner well reflect allocate healthcare common publication atm index expect later need develop country theme address region pursue flexible pricing strategy work innovative partnership try reach people access medicine vaccinesgsk corporate responsibility report health improve access healthcare global challenge increase availability addition research improve affordability price factor prevent disease work tackle development innovative product focus impact access medicine vaccine root cause disease illhealth contribute tackling disease particularly prevalent develop adopt range innovative pricing model reflect healthy community world example country include neglect tropical disease commitment work government vaccine play major role prevent disease work improve availability medicine increase stakeholder deliver medicine vaccine acknowledge product registration market include people need possible costeffective health investment estimate new product make sure exist product seek method improve affordability million death prevent widely available broaden portfolio innovative financing mechanism small pack size child save disability vaccine relevant health need people year vaccine approve flexible pricing help build business develop country marketing address medical need develop emerge market increase overall volume develop country cover lead strategic alliance acquisition help grow product sell ability offer notfor cause childhood mortality business develop country bring big profit highly preferential price world poor range affordable medicine wide population country sustainable continue work partnership improve currently supply medicine vaccine directly adequate return medicine vaccine health example partnership eliminate majority ldc look opportunity betteroff market challenge lymphatic filariasis phase handwash expand presence country africa uncertain economic climate government seek campaign read partnership ngo organisation example contain healthcare cost recognise challenge recently relaunche gsk angola zimbabwe working government europe usa establish initial distribution route somalia find solution seek price medicine fairly operate fragile state challenge important country level reflect value patient order bring medicine need payer read approach invest profit business ldc project strengthen healthcare infrastructure country support innovative africa shoulders global disease burden approach healthstore foundation global health workforce family health child family wellness nurse run franchise health post read work global health budget partner ehreth global value vaccination vaccine world health organization world health report work healthgsk corporate responsibility report health develop country challenge increase access increase availability oversight management healthcare particularly difficult improve access healthcare core gsk overall develop world world develop country strategy prioritise high level urgent need new well medicine company ceo sir andrew witty closely involve vaccine use develop country ldcs disease burden speak publicly commitment great resource tackle view set article global health issue commit find innovative way help publish lead journal health affairs address gap integrate research develop lack world pharmaceutical vaccine president gsk emerge market asia pacific organisation stimulate gsk region abbas hussain lead access effort develop country population million significant investment country review corporate executive half live day team corporate responsibility committee emerge market asia pacific business challenge include weak infrastructure supply chain board unit cover develop country support provision medicine vaccine small specialised unit dedicated develop drug overstretch health workforce low population literacy develop country market access dcma patient country championing need level food insecurity middleincome country operate unit set specifically increase patient operation focus late stage mic brazil china india indonesia thailand access gsk medicine vaccine expand clinical product match need patient large number people live extreme poverty presence build sustainable business country develop country area unit working include healthcare demand outstrip available resource manager gsk business ldcs report unit adapt gsk product well meet need challenge bad increase incidence enable tailor consistent integrate approach patient develop country noncommunicable disease asthma diabetes increase access country reflect specific need unit work gsk country manager create well evidence base formulation ebfs improve access healthcare develop country develop country increase access fixeddose combination generic medicine offer require holistic approach embrace prevention flexible pricing approach dcma unit aim improve clinical outcome low price consistent treatment effort fundamentally strengthen health increase availability gsk medicine broaden late evidence scientific literature system stakeholder need contribute portfolio relevant people treatment guideline commit play country price increase access unlock partnering research institute government invest develop country include ldc demand contribute education awareness innovative research understand longterm help ensure sustainable successful business expand distribution supply chain capability healthcare priority mix fund technology region grow country develop transfer talent development recently establish future strategy group use term develop country include fsgs review approach key business issue investigate new way reach patient include develop country identify address strategic challenge lead small pack size mobile phone currently country include south sudan ceo office bring senior manager country subsaharan africa lowincome expert business fsg focus middleincome country define world bank topic neglect tropical disease ntds hugely diverse group approach reflect access medicinesgsk corporate responsibility report health develop country increase availability group focus specifically highlight ddw portfolio disease develop world ddw include ntds prioritise research decision socio portfolio include project number disease particular relevance develop country include bacterial economic public health benefit meningitis chagas disease chlamydia dengue fever hivaid human african trypanosomiasis leishmaniasis malaria pandemic commercial return significant portion drug flu pneumococcal disease tuberculosis gsk company research new vaccine treatment discovery work take place dedicated facility tre world health organization priority infectious disease hivaid malaria canto spain similar group active vaccine highlight pipeline develop world illustrate organisation belgium hivaids viiv healthcare industryleade pipeline potential antiretroviral medicine include enter new research partnership focus compound phase phase iii development altogether compound investigation ddw include development potential new hiv treatment read viiv healthcare progress phase iii development programme commitment research collaboration relate research kinetoplastid development support population hard hit epidemic parasite responsible disease involve aids vaccine research decade pursue separate collaboration provide access vaccine strategy successful aid vaccine combine approach proprietary compound library gsk hiv vaccine candidate fas currently phase clinical trial hivinfecte subject evaluate collaboration build early stage drug discovery safety efficacy effort tuberculosis fas vaccine candidate combine recombinant adenovirus vector collaboration international aids vaccine initiative iavi continue play active role commitment gsk work pasteur institute paris partner develop aids vaccine fusing support effort develop new well gene hiv virus measle vaccine vector phase clinical trial start treatment ntds collaborative partnership collaborative discovery programme aim identify hiv envelopebase protein vaccine capable drug neglect disease initiative produce broadly neutralise antibodie hiv infection conduct multiple partner dndi notforprofit organisation share knowledge research intellectual property group malaria read progress malaria vaccine candidate dndi support drug discovery effort develop tafenoquine potential treatment radical cure plasmodium vivax malaria disease include sleep sickness visceral leishmaniasis frequent widely distribute cause relapse malaria affect million people year mainly south east asia latin america tafenoquine develop partnership medicine chagas gsk founder member wipo malaria venture mmv enter phase iiiii study initial study understand tafenoquine research consortium gpd deficiency common gene deficiency area malaria prevalent affect choice malaria treatment begin interim result expect tuberculosis world second lead cause death infectious disease work aeras global vaccine foundation tuberculosis vaccine initiative develop vaccine candidate date conduct phase trial tbnave tbinfecte bcgvaccinated adult hiv positive adult take combination antiretroviral phase trial african infant ongoing dengue fever joint initiative fiocruz walter reed army institute research develop vaccine dengue fever continue scientist gsk fiocruz work facility brazil belgium partnership enhance brazilian capacitygsk corporate responsibility report health feature approach malaria past decade see significant progress fight malaria lead commentator believe world zero death disease possible progress certainly encourage global death reduce african country implement extensive control programme limit transmission despite recent success half world population remain risk malaria kill people year child age subsaharan africagsk corporate responsibility report health feature approach malaria approach trial final stage evaluate vaccine partnership candidate infant young child regulatory believe comprehensive approach malaria single organisation ability defeat malaria file submission conduct centre seven require scale use establish tool inroad country subsaharan africa control continue invest development formation innovative partnership rtss use innovative new tool widespread result need develop partnership mvi receive introduction impregnate bed net complement million grant bill result weekold infant expect use effective antimalarial medicine melinda gates foundation advance clinical end require public health information turn complement method indoor residual development rtss prominent african include safety efficacy datum phase iii spray insecticide successful vaccine research centre programme deem satisfactory world health weapon armoury organization indicate policy recommendation collaboration medicine malaria venture pivotal year rtss malaria vaccine candidate possible mmv develop tafenoquine potential early potentially pave way decision treatment radical cure plasmodium vivax believe vaccine simple cost african nation introduction vaccine malaria frequent widely distribute cause effective way save live landmark national infant immunisation programme recur malaria affect million people gsk near year search malaria vaccine october year mainly south east asia latin america result ongoing largescale trial pricing publish new england journal medicine pledge pricing barrier reveal malaria vaccine candidate rtss exist tool benefit malaria vaccine potential reduce risk malaria half african approve recommend use eventual price work partnership child aged month year period rtss set cover cost produce organisation increase availability uptake vaccination develop rtss partnership vaccine small return preventative measure improve management path malaria vaccine initiative mvi reinveste research development malaria particularly young child subject evaluation safety quality secondgeneration malaria vaccine research pregnant woman efficacy vaccine candidate benefit neglect tropical disease commit million risk regulatory public health authority invest million vaccine far african malaria partnership amp datum bring cusp world malaria expect invest million encourage behavioural change sleep vaccine potential significantly improve year expect recoup cost insecticidetreate bed net seek treatment outlook child live malaria endemic region sale vaccine little market early stage disease africa addition malaria vaccine exist vaccine develop country ability control intervention potentially help prevent community tanzania ghana nigeria kenya significant investment return innovative million case reduce burden currently work partner national medicine portfolio enable support hospital service freeing muchneede bed treat malaria control programme help build capacity important work donate million patient live remote village little community health worker mobilise family dose vaccine mvi access healthcare frontline fight malariagsk corporate responsibility report health develop country increase availability open innovation open lab build partnership approach contribute patent patent application take tre canto site establish wipo research cover small molecule formulation need think differently conduct work closely publicprivate direct develop treatment delivery technology find new way work key stakeholder partnership group medicine malaria ntds compound partnership essential pursue venture global alliance drug development screening show evidence activity malaria open innovation approach work industry scientist work centre academia ngo government include wipo research incorporate point datum post fund partner share expertise resource scientist information expect point likely discontinue world tre canto open lab share intellectual property follow transition period share intellectual property knowhow research gsk commit share intellectual property sharing research information datum help stimulate research outside gsk knowledge help speed research ntds publish research finding open datum ddw research helped establish pool open help identify potential new treatment malaria help stimulate research outside gsk innovation neglect tropical disease point research result yearlong screening tre canto open lab contribute patent patent application process gsk scientist review commit consider request access million compound gsk chemical library seek open laboratory tre canto site spain knowledge experience term point inhibit malaria parasite space visit scientist university notforprofit medicine treatment ntds develop process identify compound show partnership research institutes pool patent intellectual property available great activity molecule barcelona centre international health research develop country royaltyfree basis proprietary gsk time cresib weill cornell medical college usa current project underway tre canto open available wide research community imperial college london work project lab result information share point develop world learn expertise share share compound set group worldclass facility gsk found member wipo research researcher encourage share new collaboration private public sector result available aim identify project begin open lab organisation design accelerate ntd research dataset publicly available act seven approve begin project launch new platform provide searchable catalyst stimulate research ddw support tre canto open lab foundation public database available compound resource charity establish million funding gsk expertise knowledge researcher project support partner bill treatment develop intellectual property melinda gates foundation wipo research website available govern board lead scientist provide royaltyfree develop country strategic direction foundation project contribute research helps discover new medicine disease develop worldgsk corporate responsibility report health develop country increase availability strengthen healthcare infrastructure highquality affordable essential medicine place support vaccination training counterfeit substandard drug common chronic shortage train frontline health worker support work network ldc recognise fundamental cfw franchisee receive support healthstore education support immunisation nesi constraint achieve millennium development form startup loan initial training coaching system promote vaccinology training healthcare worker goal world health organization estimate wide marketing support peer network recognition subsaharan africa north africa middle east shortfall million frontline health worker technology innovation nesi key partner organisation particularly africa parts asia gsk support expansion grant unicef gavi implement increase number frontline health worker implement cfw clinic rwanda second phase vaccination programme region immediate costeffective way save life plan ultimate goal establish continue support global public health training improve health outcome especially mother clinic trope network trope encompasse child example setting fully train approximately european university wellsupporte community health worker institutional partner globe effectively deliver treatment provide health education child year mobile phone tackle counterfeit nigeria commit partner find solution healthcare delivery ldc counterfeit medicine illegal gsk pilot innovative approach service look code reinvesting profit country dangerous problem protect patient africa send verification text local healthcare infrastructure support global acute counterfeit medicine mobile consumer tollfree effort expand access frontline healthcare worker develop world regulation phone take advantage high phone number consumer law enforcement capacity mobile phone penetration rate question support frontline health worker coalition relatively weak counterfeit africa average fhwc new coalition company ngos urge response consumer medicine account great strategic investment frontline health february begin text enthusiastic receive product sell africa worker develop world costeffective message sixmonth pilot text unique user way save live mother child address anticounterfeite programme represent approximately use aids global health threat nigeria antibiotic ampiclox ninety cent text return pilot run collaboration genuine confirmation received work healthstore foundation nigerias national agency counterfeit alert receive transition family health private enterprise food drug administration message indicate duplicate pin develop child family wellness cfw control nafdac place call franchise system enable local nurse scratchoff code helpdesk help operate basic medical clinic rural slum area ampiclox antibiotic pack consumer identify counterfeit ampiclox blisters africa cfw clinics target disease condition send code text message nigerian market intend cause illness death local central nafdac tollfree phone roll approach product community include malaria diarrhoeal disease number verification mobile country east africa respiratory infection maintain secure supplygsk corporate responsibility report health case study develop country increase availability reinveste profit ldc world ldc lack basic healthcare infrastructure lack access quality health facility service affect support innovative elearning project qualified healthcare worker prevent million people poor woman newborn infant farwestern tanzania upskill nurse remote region get treatment need gsk reinvest region nepal gsk support initiative lead betterinformed healthcare advance profit pharmaceutical care international upgrade local community health good practice able provide high standard consumer healthcare business ldc local service centre birthing centre improve facility care rural community work closely healthcare infrastructure partner leading provide training mobilise female education institution ministry health ngo amref care international save child community health volunteer amref develop distance learn course specifically address shortage train frontline healthcare worker fund available investment million base profit medicine consumer healthcare product afghanistan enable initiate programme train health worker initiate project nepal country end track implement project profitmake ldc bangladesh june mauritania mali niger myanmarlaos chad goal include senegal yemen ona sudan djibouti cambodia measure impact project include guinea sierra leone central ethiopia inu ltr sorker train improvement liberia tog enin uic lin uganda engage organisation help achieve democratic republic rwanda goal million health worker develop congo burundi countries tanzania example activity investment angola zambia support outlined mozambique madagascar niger child die haiti help prevent work save child initiative maradi region conduct health education session initiative lesotho communities training community initiative health volunteer deliver health nutrition message acknowledge sudan split north south session focus cause malnutrition run programme country way prevent common childhood disease ldc profit programme implement midgsk corporate responsibility report health develop country improve affordability improve affordability focus noncommunicable disease innovative pricing noncommunicable disease ncds ncds ncds represent disease burden ldc cap price patent medicine prevalent develop country improvement develop country measure disability vaccine price tackle childhood infectious disease lead adjusted life year dalys accept measure reflect unique situation hivaid viiv people live long change lifestyle disease burden daly equivalent healthcare offer notforprofit price hivaid cardiovascular disease cancer diabetes chronic lose year healthy life chart medicine ldc subsaharan africa respiratory disease account death lowincome country offer tiere country rich poor prevalence global burden disease pricing gsk vaccine worldwide grow fast middle lowincome country increase access medicine ncds dalys million introduce similar price reduction particularly challenging cost provide high income country nonldcs reduce risk product diversion longterm lifelong care gsk commit want reduce likelihood notforprofit find innovative solution challenge preferentially price medicine illegally ship middle income country sale betteroff country undermine september general assembly host purpose reduce price improve high level meeting new york devote ncds low income country access poor country gsk participate meeting work member ifpma international federation low middle income country middleincome country implement range pharmaceutical manufacturer association approach balance commercial objective publish framework action industry need increase access medicine patient focus area prevention innovation access market afford pay include communicable disease capacity building partnership key output noncommunicable disease flexible pricing model tailor product local meeting political declaration prevention source manufacture arrangement control ncds provide mandate explore opportunity medicine member states ncds priority available small pack size declaration call focus prevention affordable patient pay prescription foster multistakeholder approach include ncds pricing access initiative look new way improve access sustainable business model example include work develop lowcost asthma product global status report noncommunicable disease specifically patient develop world ifpma framework increase focus ncds provide political declaration prevention control ncds opportunity work government global burden disease report update nontraditional way try expand access disabilityadjuste life yearsgsk corporate responsibility report health develop country improve affordability pricing cap develop country ldc sale volume majority product increase pricing vaccine significantly follow price decrease believe reduced price ldc year entire vaccine increase access product patient gskpatente product individual product line portfolio available expand immunisation formulation sole supplier reduce price offpatent programme preferential price develop market price cap antibiotic augmentin zinnat certain country tiered pricing system price france product sell country see increase sale volume price link gross national income define provide price cover manufacturing cost example decrease price zinnat world bank size order offer sustainable price reduce average bangladesh volume increase yearon length particular supply contract selling apply follow brand year product range vaccine large volume long term contract seretide asthma chronic obstructive pulmonary vaccine sell small private market ldc able significantly reduce price disease copd offer western european average individual dose gavieligible country price avamys rhinitis gavi alliance unicef purchase large little tenth develop country flixotide asthma volume vaccine world poor child model work vaccine demand relatively benefit gsk low price predictable nature vaccination prevention malarone malaria compare use medicine treatment avodart benign prostatic hypertrophy measure impact price reduction introduce flexible pricing vaccine sell directly increase sale volume receive fraxiparine anticoagulant government customer anecdotal feedback physician indicate ultiva anaesthetic patient medicine patient extend advance market commitment arixtra venousthromboembolism vte compliance prescribe dose improve amc agreement gavi alliance speed access zeffix hepatitis case pneumococcal vaccine synflorix supply million dose synflorix gavieligible country case price country price reduction pass patient work cost develop market respiratory government medium pharmacist pneumococcal disease leading cause death pharmaceutical distribution network children develop country vaccine medicine transparency alliance sure patient help protect million child aware benefit reduction decade synflorix introduce kenya beginning sale volume increase country cap ethiopia far launch expect amc design accelerate access vaccine bystimulate manufacture vaccine affordable price longterm agreement price patent average price reduction manufacturer synflorix introduce africa month introduction europe medicine vaccine brand ldc compare pricesgsk corporate responsibility report health develop country improve affordability rotavirus infection leading cause middleincome country flexible pricing believe approach impact childhood mortality develop country gsk example innovative pricing approach middleincome country mic brazil supply rotavirus vaccine rotarix gavi outline china india indonesia thailand grow market alliance dose small fraction develop gsk represent important source future avamys oncedaily nasal spray treat allergic world price commit supply million business strategy grow business mic rhinitis reduce price avamys dose rotarix year enable make product affordable low average mic volume avamys sell gavi meet aim expand rotavirus vaccination income level turn increase volume increase fourfold introduce flexible pricing country sudan product sell introduce flexible increase number pack sell country africa introduce rotarix support pricing approach account difference offset impact lower price gavi alliance economic status demography healthcare infrastructure enable reduce cost good synflorix rotarix agreement gavi pricing regulation patient affordability introduce tiere pricing oncology product contribute potential immunise million flexible pricing approach include tykerb breast cancer treatment emap child substantial contribution improve affordability link pricing policy market example india reduce price achieve millennium development goal reduce closely countrys gross national income gni tykerb july see growth child mortality twothird volume previous year datum introduce differential pricing market reach suggest patient adherence tykerb treatment supply portfolio vaccine affordable price new sector population base assess patient improve pan american health organization paho ability pay purchase behalf middleincome develop work closely health authority payer brazil decrease price antibiotic country latin america caribbean agree innovative pricing programme medicine treatment augmentin volume arrangement help protect estimate support disease awareness campaign increase yearonyear range million infant rotavirus rotarix estimate closely monitor price compare local million baby pneumococcal infection competition regularly review synflorix girl cervical cancer cervarix develop guidance flexible pricing new product launch emerge market asia pacific emap region market access pricing team work local operating company establish right pricing approach market help share information good practice market access child potentially amc synflorix immunise price cost gavi agreement develop market synflorix rotarixgsk corporate responsibility report health develop country improve affordability innovative financing model medical insurer cover cost treatment local manufacturing strategic alliance patient respond week gsk refund innovative financing break barrier access achieve high sale volume help reduce cost cost treatment patient disease improve affordability patient example good pass price reduction progress week initiative demonstrate treatment postmenopausal woman risk bone ultimately increase access product addition belief product efficacy ability deliver fracture osteoporosis prolia denosumab commercial team collaborate manufacture equivalent benefit treatment low cost administer injection month organisation explore local source manufacturing way convenient patient pilot new patient access scheme pas argentina licensing arrangement brazil chile philippines singapore ukraine introduce discount card ukraine argentina vaccine business number joint pas benefit patient pay chile vietnam help group patient venture technology transfer arrangement prescription cost market adopt senior citizen disable people lowincome patient help increase supply affordability vaccine approach well suit need example argentina chronic disease able afford enable develop country develop launch programme allow patient pay copayment element prescription medicine research manufacturing capability increase prolia interest free instalment reduce initial partner example morocco market access gsk read approach expense make prolia accessible patient work lalla salma association cancer technology transfer position paper online option make prolia accessible ngo provide oncology medicine tykerb population increase arrangement include agreement zofran significantly reduce price mean binnopharm russia cover vaccine human introduce riskshare model number patient limit mean insurance estimate papillomavirus hpv rotavirus streptococcus market help speed patient access population treat public longstanding partnership brazil oswaldo cruz treatment need demonstrate value hospital charge foundation cover polio haemophilus influenzae product help government manage type hib measle mump rubella rotavirus spending example brazil launch pneumococcal disease china initial joint performancebase financial risksharing scheme venture shenzhen neptunus newly breast cancer treatment tykerb know tyverb whollyowne subsidiary develop manufacture give access million extra patient influenza vaccine brazilian government policy reimburse oral oncology treatment tykerb physician tend prescribe intravenous treatment invasive mean patient spend time hospital new scheme tykerb prescribe patient assess week treatmentgsk corporate responsibility report health develop country prevent disease raise awareness prevent disease raise awareness respiratory disease develop world raise awareness fundamental aspect good health management clear medical need develop world ensure people informed avoid major contribution prevent disease get ill look fall ill people education awareness chronic respiratory illhealth significant contribution adequately informed right condition particular asthma assess current vaccine business product precaution seek appropriate treatment reach respiratory business fully understand include hivaid viiv healthcare necessary malaria good example barrier access analyse asthma control diabete prevent disease progress severe significant effort invest encourage people perception asthma access healthcare form consumer product help prevent tooth sleep insecticide treat bed net look develop country reveal high decay help people stop smoke improve nutrition early sign malaria effort contribute level poor asthma control inadequate treatment phase community investment programme significantly recent decline mortality frequent hospitalisation asthma attack stigma contribution global alliance eliminate lymphatic malaria suggest well training healthcare filariasis outline professional public awareness campaign pharmaceutical business flexible pricing programme target address affordability vaccine approach accompany comprehensive access issue improve respiratory problem gsk vaccine include immunisation campaign campaign increase awareness turn sure market country worldwide billion vaccine maximum number patient benefit respond number approach dose deliver million dose price reduction increase access example include roll programme regional ship use develop country indonesia reduce price respiratory masterclass awareness education include develop low middleincome number establish brand session key region review country gsk lead vaccine supplier set price realistic level reflect countrys supply chain cost reduction opportunity explore organisation unicef pan american ability pay disease education medium awareness innovative pack presentation approach health organization paho campaign support gsk launch event support access include fill gap physician hold attend minister september agree donate million worth current product portfolio health effort expansion cervical cancer vaccine cervarix usbased pink healthcare professional coverage addition come longterm agreement ribbon red ribbon partnership covering country help increase access supply ventolin inhaler global asthma drug girl women africa access vaccination medicine example volume seretide facility adf adf procurement programme year gsk pledge asthma treatment double follow aim essential asthma medicine available support pink ribbon red ribbon programme operation approximately price reduction affordable low middleincome country help expand availability vital prevention screening treatment programme cervical breast furthermore work raise awareness cancer develop country partnership disease improve prevention treatment focus integrate lowcost screen treatment develop country example phase service aim reduce death cervical cancer handwash programme participate area africa yearsgsk corporate responsibility report health case study develop country prevent disease raise awareness approach neglect tropical disease ntd billion people afflict expand donation albendazole elimination programme ntds list year conservatively estimate expand albendazole donation world health organization billion programme target ntds disease mainly affect people lymphatic filariasis soil intestinal worm infection stunt marginalise poverty live transmit helminth sth intestinal growth cause anaemia remote rural area urban slum worms pledge extend malnutrition impact child conflict zone limit access additional year commitment ability learn affect performance effective healthcare clean water donate million albendazole school scale donation sanitation adequate nutrition proper treatment year help achieve target housing transportation education enable deworme schoolage child reach school child impact ntds prevent personal endemic country globally live country community national economic intestinal worms endemic development perpetuate poverty establish commitment donate albendazole long start ship tablet january join global necessary know schoolbase deworme ahead schedule pharmaceutical company lead elephantiasis eliminate currently togo rwanda ship organisation include provide nearly million tablet year mozambique namibia argentina bill melinda gates foundation help eliminate disable guinea preparation activity department international debilitate parasitic disease spread announce extend development agency mosquito work global programme africa include international development usaid alliance eliminate lymphatic filariasis endemic region meet commitment new united effort support develop continue grow help reach invest new manufacturing country defeat ntds coalition billion people risk line factory south africa support ambitious goal set donate billion control eliminate collective commitment donate albendazole treatment ntds end decade billion albendazole treatment country ship include eliminate disease million tablet soil year aim help country fight billion elephantiasis intestinal worm lymphatic filariasis elephantiasis guinea transmit helminth sth worm blinding trachoma sleep country complete sickness leprosy control mass drug administration soil transmit helminth albendazole treatment process confirm absence intestinal worm schistosomiasis economic benefit result year donate year disease transmission overall global programme eliminate lymphatic river blindness chaga visceral commitment target economic benefit global filariasis plos public library science leishmaniasis ntds june volume issue sth infectiongsk corporate responsibility report health case study develop country prevent disease raise awareness measure impact phase programme year million people die diarrhoeal disease show programme continue change child spread disease behaviour reduce incidence disease easily prevent improve water quality country implement encourage people wash hand personal example bangladesh number family hygiene sanitation education phase programme wear sandal latrine avoid worm run partnership ngo tackle issue infestation increase reduction diarrhoea incidence participate school reduce improve local water pipe pump infrastructure phase teach child wash hand important easy understand phase recently implement high book story card adapt reflect density urban settlement example nairobi mumbai everyday live country programme rio janeiro extended partnership encourage child share learn earth institutes millennium village project family community integrate oral healthcare phase poor oral hygiene significant problem develop country phase begin programme reached affect individual overall health quality life million child information aim introduce test effective measure change behaviour healthy behaviour change promotion good oral conduct second strategic review assess impact health practice nutrition eat habit behaviour health research carry water engineering development centre goal set model integrate phase loughborough university school deworme expand albendazole donation programme phase global overview publish website june gsk corporate responsibility report health develop country advocacy advocacy support development pilot advance market future plan commitment pneumococcal vaccine appropriate work government policy believe contribute effort present behalf industry meeting maker encourage change policy environment improve health develop country consultative expert working group help increase access healthcare sustainable continue develop product portfolio suit financing meeting way include work company sector disease burden suffer patient develop foster industrywide approach work government global health issue country continue include cochair uks industry government support approach encourage adequate forum access medicine participation introduce flexible pricing strategy work investment healthcare infrastructure support partner forum government global increase access middleincome country innovation support differential pricing adequate health strategy seek partnership encourage scientist work financing mechanism gavi global participate executive board meeting research centre disease fund fight aid malaria factor world health assembly develop world tre canto spain critical sustainably improve access long term participate board member gavi alliance encourage consider innovative approach example include roll malaria participate gavi realise potential wipo research cochaire gatesceo roundtable lead replenishment conference funding immunisation seek reduce price patent medicine january ntd conference play child develop country ldc major role engage intergovernmental meeting reinvest profit sell medicine ceo sir andrew witty participate event pandemic influenza preparedness ldc help strengthen healthcare infrastructure state department lead formation participate numerous meeting present country encourage consider coalition private sector company help tackle event access medicine intellectual property similar scheme lack frontline healthcare worker european parliament venue integrate phase school deworme participate launch gfinder report expand albendazole donation programme neglect disease read online publish detail online key issue include access develop country public health intellectual property product donation price reimbursement market access wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report health develop country age population rise reimbursement medicine subject specify demonstrate value research condition help address uncertainty incidence chronic disease mean exist case launch product collaborate european healthcare healthcare budget strain performance budget impact example italy innovation leadership network ehiln improve understand different stakeholder group gsk reimburse cost tyverb breast develop country constitute medicine value find way cancer therapy case failure interruption well demonstrate research process therapy week treatment recognise government balance desire participate pilot project healthcare equality need manage limited work closely government help stakeholder advise gsk development strategy financial resource ongoing financial crisis manage healthcare cost example czech republic earlystage diabete product task increase access product national immunisation committee recommend refined well demonstrate medicine value challenge universal mass vaccination pneumococcal vaccine second pilot project launch december government funding available implement innovative oncology product engage aim work closely government payer special team set gsk czech republic discussion policy maker development healthcare system ensure product available partner payer doctor distributor epidemiologist consistent euwide approach assess value affordable seek understand need politician help overcome challenge new medicine healthcare priority sure establish new reimbursement distribution system demonstrate value product establish access medicine centre pneumococcal vaccination include reimbursement process evidencebase datum time excellence european pharmaceutical system fund health insurance company hics launch allow fair price set business working payer healthcare system new supply chain distribute vaccine clinic reflect medicine prove value affordable understand thinking need insight funding system establish offer volume customer sustainable gsk gather advisory board regular discount structure synflorix pneumococcal vaccine engagement bring process accept hic place europe ensure evidence need fully consider newborn population cover medicine development plan develop solution europe financial crisis unprecedented new funding distribution system healthcare system challenge clear priority pressure public budget achieve good result direction business gsk commit help individual member states patient taxpayer industry believe manage funding gap protect development work genuine partner government help innovative valueadde medicine vaccine find solution bring value healthcare system european trade association efpia support costmanagement maintaining participate discussion national government incentive innovation imf european commission european support differentiate approach central bank agreement reach support tailor particular national context allow country manage pharmaceutical spending company offer price affordability concern way work meet overall account appropriate come financial commitment form innovative pricing approach enable accessgsk corporate responsibility report health develop country usa usa member access industry tackle chronic disease programme give uninsure citizens usa million people live discount medicine gsk programme usa way healthcare delivered pay federal poverty limit difficulty open people earn time federal evolving gsk commit helping identify pay healthcare patient poverty level nearly million americans enrol solution improve healthcare reduce cost eligible government programme medicaid access patient particular focus chronic disease need assistance obtain prescription receive day prescription gsk medicine responsible healthcare cost usa medication need gsk programme access programme give current system patient visit number provide medicine free eligible patient patient discount different specialist aware health uninsured underinsured earn inception access give service patient receive healthcare money afford medication million patient saving total million provider test result treatment patient receive gsk wide range product medical condition prescribe medication medicine vaccine worth million million launch patient assistance programme result care episodic uncoordinated programme value calculate benlysta lupus treatment develop gsk team community care north average cost good wholesale codevelopment cocommercialisation carolina innovative publicprivate collaboration acquisition cost measure pharmaceutical agreement human genome science make call north carolina health aim company believe approach value medicine medicine available cost patient demonstrate coordinate care help reduce accurately reflect true cost gsk value insurance meet certain eligibility qualification cost healthcare improve patient outcome wholesale acquisition cost value medicine launch copayment assistance participant include state health plan north programme million programme help eligible patient carolina pharmacy chain kerr drug sas blue gsk operate programme patient meet outofpocket cost benlysta cross blue shield north carolina state large certain eligibility requirement include commitment information viiv healthcare health insurer access cancer treatment bridge access patient assistance programme health use patientcentere medical home medicine outpatient vaccine access cover model mean patient primary care adult vaccine hepatitis hepatitis tetanus physician coordinate patient healthcare diphtheria pertussis cervical cancer gsk access provider health information technology provide extra help lowincome senior care manager provide comprehensive disabled patient enrol medicare picture patient health enable coordinated approach gsk enable employee north carolina participate programme employee enrol begin januarygsk corporate responsibility report health hivaid viiv healthcare viiv healthcare establish gsk research development evaluate new approach twodrug versus threedrug oncedaily combination treatment pfizer independent viiv healthcare commit development new patient infect ccrtropic hiv company solely focus need product target unmet medical need hiv include treatment child living viiv healthcare support international hiv people live hiv long age hiv tackle problem collaborative research trial resourcepoor setting drug resistance complex treatment regimen partnership broad range external organisation commit deliver innovation effect associate current treatment academic institutes uks medical improvement people live hiv viiv healthcare currently molecule research council national institutes health world section outline approach investigation development potential new hiv focus public health relate issue progress find online treatment include compound phase prevention mothertochild hiv transmission paediatric wwwviivhealthcarecom phase iii development adult treatment strategy start treatment hivtb coinfection viiv healthcare donate arvs viiv healthcare aim reenergise pharmaceutical joint venture shionogi viiv healthcare provide financial support scientific input industry participation hiv deep develop novel oncedaily unboosted investigational life study broad understanding need live hiv integrase inhibitor sgsk know virus treat fix dose combination trii epzicom end trial underway kivexa phase iii clinical trial continue plan involve patient gsk pfizer hiv medicine market viiv trial involve african country healthcare broad portfolio medicine hiv simplification therapy oncedaily dose paediatric study provide annual sale billion mean priority term patient quality life significant clinical datum efficacy safety financial stability investment capital require potentially improve outcome october viiv pharmacokinetic viiv healthcares nrti score tablet sustainable longterm view hiv market healthcare launch largescale phase iii clinical resourcepoor set trial oncedaily dose celsentriselzentry combination protease inhibitor hiv patient previously untreated antiretroviral arvs molecule development trial underway end potential new involve hiv treatment patientsgsk corporate responsibility report health case study hivaid viiv healthcare research development treatment child hivaid infant child live hivaid develop joint effort improve access therapy care include initiative test hivexpose country access effective treatment viiv healthcareelizabeth glaser pediatric aids infant week birth recommend launch viiv healthcare commit foundation partnership egpaf aim increase successfully scale programme million paediatric innovation seed fund early detection hiv improve access arv therapy result great number infant initiate support research development meet need hivpositive infant young child strengthen antiretroviral treatment testing hiv positive patient fund support partnership government leadership policy paediatric partnership catalyse new formal informal organisation focus evidence base hivaid improve quality use paediatric collaboration organisation deliver paediatric care paediatric care treatment research care partnership sought resolve critical linkage health facility community development paediatric fixeddose combination fdc barrier treatment child improvement strengthen product formulation treatment infant early infant diagnosis treatment subsaharan viiv healthcareamfar treat asia programme child live hiv africa focus lesotho swaziland malawi aim optimise quality healthcare infant child live hiv asia development clinical datum support paediatric treatment guideline initiation treat asia partner work address knowledge gap paediatric care treatment establish research study educational workshop advocacy project nonmonetary memorandum understand clinton health access initiative chai aim develop affordable new fdc paediatric usegsk corporate responsibility report health hivaid viiv healthcare increase access increase access innovative pricing voluntary licensing viiv healthcare commit play viiv healthcare offer complete arv portfolio notfor royaltyfree voluntary licensing approach address access medicine challenge take profit price ldc world bank lowincome viiv healthcare enable generic company manufacture innovative responsible sustainable approach country subsaharan africa country sell version product ldcs lowincome accord unitaid cover people currently countrie subsaharan africa accord unaid million live hiv notforprofit price combivir estimate million people live hiv eligible viiv healthcare grant voluntary licence patient year cent day compare treatment low middleincome country arvs increase company form access antiretroviral therapy unaid licensee supply million commit reach million people live significant improvement affordability version epivir combivir african country hiv antiretroviral treatment recognise price affordable world poor viiv healthcare anticipate volume lamivudine world total unaid estimate million people community significant additional healthcare licensee decrease follow patent expiry live hiv low middleincome country resource available ongoing commitment support access hiv therapy fold increase middleincome country income high affordable second line regimen viiv healthcare anticipate viiv healthcare recognise key stakeholder infrastructure develop flexible generic version broad portfolio endeavour global effort commit work pricing policy factor gross domestic product measure report datum future reporting partnership hiv community address gdp impact epidemic country challenge industryleade access initiative improve affordability country include continually evaluate look fast grow economy world supply combivir epivir tablet improvement viiv healthcare access medicine need government commitment accountability licensee approach cover mic lowincome country scale national response hiv epidemic ldc subsaharan africa country total number tablet million viiv healthcare ship tablet notfor variety approach base profit combivir epivir develop country compare differ need people live hiv different million decline supply viiv part world healthcare arvs expect outweigh volume supply licensees viiv healthcare licensees gsk licensee datum include additional licensee comparable datum available datum consider conservative estimate use licensee capture data datum include paediatric formulation syrup viiv healthcare aware significant use zidovudine lamivudine generic fix dose combinationsgsk corporate responsibility report health hivaid viiv healthcare community investment local partnership technology transfer community investment positive action child fund approach take viiv healthcare middleincome viiv healthcare support community affect hiv collaboration partner aim provide country create partnership incountry aid positive action programme positive support deliver prevention mothertochild pharmaceutical company manufacture medicine action child fund positive action community transmission hiv pmtct service year locally bring cost therapy grant read wwwviivhealthcareeffectcom continue form new partnership community invest sharing expertise build skill local focus organisation strive alleviate devastate positive action programme economy partnership binnopharm russia effect hivaid pandemic positive action enable local secondary manufacture viiv healthcare positive action programme create child fund integral viiv healthcare arvs people live hiv russia example work marginalise vulnerable community commitment community affect hiv aid include young people girl woman sex worker company commit invest million medicine patent pool foundation mppf man sex man homeless inject million fund year medicine patent pool international drug user launch march positive action community response meet challenge improve access treatment care people live viiv healthcare continue great progress child fund commit million project affect hiv aids community partnership connection collaboration country partner organisation demonstrate broad hiv community funding enable commitment dedication address mother mppf write viiv healthcare pharmaceutical community tochild transmission hiv innovation company work hiv early december maximise local resource available ask join formal discussion pool tackle stigma discrimination reduce violence health system work closely align viiv healthcare meet mppf january risk population unaid global plan elimination new hiv hold constructive meeting test innovation education care treatment infection child keep continue dialogue build grassroot capacity disproportionately mother alive work achieve patient assistance programme affect community millennium development goal set reduce child mortality improve maternal health improve access hiv medicine uninsure low february positive action programme income patient usa viiv healthcare launch international hivaids alliance announce positive action community grant patient assistance programme hiv medicine partnership vida digna extended salvador positive action community grant give january programme provide viiv healthcare additional country central america tackle viiv healthcare local operating company hiv hiv product little cost qualified patient stigma discrimination vulnerable population community organisation support innovative household income federal poverty people live hiv programme read case study level viiv healthcare pilot membership programme germany beat life online usa positive action southern initiative welvista nonprofit programme facilitate access extend state collaborative hiv medication currently wait list communityfocuse programme design address government aid drug assistance program gap service programme support care treatment address improve adherence individual live hivaidsgsk corporate responsibility report health case study hivaid viiv healthcare community investment vijana tunaweza newala globally girl young woman followup study show project likely hivpositive male helped bring change attitude peer viiv healthcare positive action sexual relationship programme fund project stimulate dialogue girl right newala develop role society local poorly resource district tanzania community provide tackle fundamental cause girl educational support girl vulnerabilitie hivaids project vijana tunaweza newala research project identify run international center key source vulnerabilitie research woman icrw taasisi gender stereotype erosion family maendeleo shirikishi arusha social support network exploitation tamasha collaboration pact early sex limited communication tanzania viiv healthcare currently support project launch discuss way expand reach life skill education programme provide programme icrw opportunity girl talk sexual community partner tanzania reproductive health empowerment selfawareness social personal issue sixmonth pilot period session hold school local community reach young people information pregnancy hiv self esteem puberty love sex goal set form friendshipsgsk corporate responsibility report people content introduction performance community work gsk feature bring engage employee science london olympic develop employee paralympic game support development diversity gsk pulse employee health safety volunteer people community community world investment respect click arrow section people support employee reach potential aim positive difference community operate economic contribution investment education programme partnershipsgsk corporate responsibility report people community introduction invest people employment practice design create work progress place culture gsk employee feel value community underpin long term respect empower inspire achieve goal continue focus diversity inclusion sustainability business create senior manager woman strong prosperous community create right total workforce employ emerge market right internal external condition business growth want catalyst asia pacific japan region change help community work condition support strategy extend employee assistance programme eap flourish business grow employee provide access counselling mental health emotional crisis support reduce day lose injury illness hour work set new reportable injury illness target engage employee idea engine facility generate idea improve aspect business performance valuesbase business extend pulse programme employee country chance contribute skill nonprofit organisation placement gsk value guide work expect involvement london olympic employee paralympic game inspire new generation young scientist improve health wellbeing commit transparency community employee respect people give million global community investment include million product donation value demonstrate high integrity conduct cost patientfocuse donate product value million area affect japanese earthquake million read apply value cash japanese red cross gsk corporate responsibility report people community work gsk aim create inclusive inclusive environment good business myceo section global intranet give employee bring different knowledge perspective experience chance pose question sir andrew witty engage work environment working style enhance creativity member corporate executive team cet empower employee contribute innovation gsk gsk employ people cet member blog page update staff country worldwide part business communicate help achieve strategic facetoface meeting webbroadcast regular aim gsk employee feel engaged business objective key broadcast sir andrew screened gsk location work colleague understand impact available watch employee computer investment development delivery business objective approach flexible working performance know key motivator idea engine facility employee employee contribution make positive suggestion improve aspect business innovative safety health impact people live give real sense purpose performance vote idea forward colleague wellbee programme run campaign generate idea engage employee vote campaign cover range theme engage employee new strategy believe relationship employee consumer healthcare business idea line manager critical factor ensure improve customer service new core business employee engagement leadership programme service function manager training level aim build leadership capability seek feedback manager year see major change business perform leader employee survey include new acquisition joint venture degree feedback process restructuring include outsource site closure staff senior leader take degree assessment reduction market global footprint receive feedback performance change reduction number employee supervise colleague manager peer western market increase employee base emerge market communicate regularly employee order provide uptodate information progress conscious effect restructure goal change business listen employee possible aim achieve feedback stimulate innovative idea organisational financial goal eliminate job consult employee representative improvement internal communication implement measure affect workforce example improve connectgsk global intranet site help people obtain information quickly program energy performance team connect colleague company personal resilience help employee sustain energy level especially time changegsk corporate responsibility report people work gsk develop employee community develop employee pay performance want gsk employer choice achieve open transparent reward total remuneration executive director invest significantly develop employee employee management executive team include value award earn level people early career senior longterm incentive plan total remuneration management position offer employee recognise reward employee contribution include base salary benefit pay range learn opportunity tailor development success business offer competitive salary performance element annual bonus value programme employee achieve sustainable base industry benchmark incentive longterm incentive awards committee high performance encourage onthejob learn acknowledge performance annual objective want reward failure payment performance challenge project work support company performance share ownership scheme principle ensure incentive payout formal training programme mentor coach management executive level remuneration align circumstance performance outcome reflect volunteer programme pulse business performance measure support genuine achievement original target number development programme delivery strategic priority emphasis level total remuneration earn support new recruit early career include reward longterm performance package grant executive director industrial placement apprenticeships esprit remuneration committee set remuneration policy final value determine year global mba programme postgraduate update level executive team give consideration time actual performance measure university relation strategy sure level wide employee population target number scenario include access great number talented graduate support responsibility ensure appropriate demonstrate range remuneration ambition increase graduate recruitment threefold excessive competitive industry wider achieve people year market norm policy structure pay commit reimburse uncapped tuition fee aware sensitive environment surround performance base set consistent rigorous undergraduate recruit executive pay time real economic challenge standard reward achievement strategic onwards investment future company priority design ensure delivery strong britain large company recognise broadly industry young people longterm financial performance sustainable leadership role importance balance recently introduce job coach programme shareholder value approach important gsk like multi business leader coach colleague national company able compete globally continuously evaluate approach consult direct line management train reward leadership vision fundamental key shareholder annually proposal policy job coach coach approximately success continue success interest listen carefully feedback believe employee country introduce shareholder global economy current approach reflect year practical coaching workplace oneday enhance disclosure annual report provide programme design help manager adopt transparency clear overview total coaching culture team believe focus remuneration earn available executive coaching help create energised director include resilient workforce highperforming leadership sgs verifiedgsk corporate responsibility report people work gsk diversity community leadership development framework support diversity gsk woman management position critical career stage build leadership pipeline provide clarity skill capability inclusive employer help attract retain require key stage extend attendance motivate workforce reflect community svp leadership programme employee operate director emerge market example manager commit make employment gsk accessible participant lead business programme total people disability increase proportion potential general manager emerge market woman people emerge market management ethnic minority usa employees line leadership programme deliver position measure proportion woman language country management position worldwide proportion future strategy group fsg prove valuable ethnic minority employee usa opportunitie high potential employee work closely usa aim people disability able access corporate executive team employee range recruitment career opportunity partner proportion people employ emerge undertake assignment challenge area access disability organisation employer forum market asia pacific japan region increase medicine malaria gain valuable experience disability serme spain total employee think operating enterprisewide level sign employer forum disability accessible senior manager report executive team think flexibly way work enable technology charter support blue chip come region plan increase attract retain critical talent group include organisation government department charter formal arrangement flexible hour parttime aim improve access people disability ethnic minority account employee work job share informal arrangement spur inclusive design proportion ethnic minority england wale census base work different location empower good representation woman management commission racial equality definition employee help optimise effectiveness position percentage woman high level encompasse identify well balance work need position grew reflect goal increase white british measure diversity commitment encourage flexibility provide proportion female employee senior level number employee define nonwhite meet broad need business employee nonwhite compare aspiration female representation board currently woman serve nonexecutive director usa ethnic minority define black representing board woman african american people hispanic latino people corporate executive team asian people pacific islander american indian people alaskan native proportion ethnic minority employee usa increase continue work industry average define north american industry classification system pharmaceutical medicine manufacturinggsk corporate responsibility report people work gsk health safety community health safety seven strategic ehs priority resilience latin america health safety management integrate gsk gsk latin america region team resilience healthy improve health employee environment health safety ehs strategy support programme energy performance workshops sustainable family disease business objective reduce risk harm significantly reduce perceive workplace pressure live prevention health promotion help employee healthy productive energised country region introduce team strategic review complete set new ehs resilience programme follow success sale energise aspiration healthy resilient highperforming force brazil employee help employee manage resilient workforce achieve zero harm people benefit personal health sustainability worker environment identify seven strategic priority participate achieve programme enable employee engage sustain high provide coaching help people ceo ehs sustainability awards key tool manager reflect way work analyse perform perform well develop engage employee health safety environmental pressure point identify action improve resilience leader solution resource issue refresh award reflect new employee perceive low pressure read strategic priority particular recognise project seven category show demonstrable benefit business healthy high enhance work strategic area year receive application response cite low mediumhigh pressure latin america perform environment improve winner feature workplace quality work life planet section work demand healthy resilient highperforming workforce culture zero gsk provide programme positive impact eliminate incident accident improve people wellbee productivity control year programme tool resource help employee lead healthy life cope well management practice embed put right value stress experience work home eh beliefs tor mtic ino wcu elt ure pilot new preventive healthcare service career development behaviour programme employee family business relationship environmental reduce environmental individual characteristic sustainability footprint read low mediumhigh sgs verifiedgsk corporate responsibility report people work gsk health safety community emotional mental health ability cope aim zero harm ceo award pressure important physical wellbeing aim zero harm immediate aspiration employee assistance programme eap provide gsk zero incident employee access counselling mental health resilience emotional crisis support extend eap risk employee vary accord role include employee begin chemical exposure drive accident repetitive strain gsk taiwans energy performance programme year injury operate rigorous procedure eliminate ceo sustainability award healthy hazard practicable protect employee highperforme workforce programme energy resilience programme help individual necessary right culture essential starting strengthen personal team resilience team effective increase focus point living safety programme initially launch highprofile holistic programme result include energy confidence reduce tension anxiety aim change perception safety fatigue additional employee participate halve employee turnover rate integrate operation increase personal resilience programme bring responsibility safety living safety module zero harm overall participation nearly employee intranet provide interactive tool improve employee manufacturing team ware energy coach new programme oneon understand risk manage evreux france zebulon usa jointly telephone coach session reduce health safety risk ceo sustainability award zero harm project coach help employee identify energy need automate analytical testing dry powder evaluate option address revitalize take step improve risk recognition injury new programme intranet tool root cause assessment general safety capability inhaler result include reduce exposure analyst employee learn recognise manage gsk particular emphasis solvent active ingredient risk repetitive emotional stress mental distraction machine process construction safety strain injury improve datum quality consistency launch professional certification programme improve throughput efficiency energy resilience programme measurable improve health safety skill eh workforce impact employee behaviour analysis find help fill ehs talent shortage develop participant improve aspect desirable market support ehs goal behaviour act coach mentor set specific target report improved lifestyle hazardous material development especially nutrition result feel healthy manufacture pharmaceutical continue key risk energetic example followup study gsk operation threeyear process safety canada demonstrate employee increase plan aim identify reduce risk train personnel engagement work follow energy key process safety element improve performance performance say programme improve instance primary manufacturing site use job performance year later process safety performance indicator number severity incident ensure risk manage sgs verifiedgsk corporate responsibility report people work gsk health safety community launch process safety programme respirator free ongoing initiative use engineering alert approach half injury secondary consumer manufacture programme process relate control reduce occupational identifie potential major hazard develop risk reduction exposure risk harmful airborne powder clifton new jersey site usa halve rate plan provide process safety training review completion project task involve injury illness create paradigm key control system complete process safety powder handle manufacture facility shift change employee approach near miss diagnostic secondary consumer site respirator free incident employee decide replace term near cover end miss safety alert term likely grab raise employee awareness importance health attention provoke action routinely perform audits ensure reduce safety commercial sale operation manage risk effectively challenge diverse group work site director challenge employee submit internal audits main theme control environment diverse geography situation safety alert quarter achieve total high risk nonroutine activity process safety range office london sale force year compare monitor system control pathological agent motorbike india need assessment field thinking alert lead audits find management health safety group lead development specific training action prevent accident risk generally adequate identify progress tool road driver safety launch employee respond enthusiastically submit process safety risk machinery safety find awareness campaign risk injury slip alert year importantly improvement need issue relate risk fall great contributor injury safety improve site go nearly month management process selfinspection relate work loss reportable injury monitoring system ergonomic addition internal audit work enhance site exceptional progress recent year audits help identify control health safety risk improve ergonomic programme continue audits carry site employee help increase employee awareness ergonomic website build well risk assess monitor culture encourage site submit solution train employee carry sitebased audits ergonomic problem create library example manufacture site help site similar situation step philosophy zero access machine adopt begin replace exist risk assessment manufacturing site result decrease application single system appropriate significant risk relate operation production open office design machinery zero access aim eliminate injury harm employee relate machine safety ensure protective machine guard place lockouttagout loto process use protect staff operation protective measure place employee suffer amputation sgs verifiedgsk corporate responsibility report people work gsk health safety community health safety performance fine penalty reportable injury illness rate work relate fatality injury health safety fine penalty assess gsk hrs work keep employee contractor healthy safe priority essential responsible injury illness target employer regrettably employee die set new target performance pakistan feeling unwell offsite demonstrate start progress training programme second employee die expect trend continue expansion seriously injure car travel live safety programme use lead ambush nigeria lead cause gsk reportable injury performance metric measure performance illness follow incident review assess broad picture injury illness cause remain process build guidance previous year lead employee guidance recognise respond slipstripsfall cause slipstripsfall machineryrelate injury heart symptom share globally machinery musculoskeletal condition repetitive stress strain advice measure reduce carjack risk motor vehicle accident motion case mental illhealth account provide employee nigeria sprainsstrain incident continue musculoskeletal condition perform routine activity site india high number lose calendar day egypt operator suffer amputation move detailed breakdown metric datum machinery employee india suffer finger detailed download available online amputation motor vehicle accident zero environment health safety datum report access driver safety approach critical assure sgs read assurance statement prevent machine road safety relate response injury harm employee sgs verifiedgsk corporate responsibility report people work gsk health safety community summary injury illness datum ehs plan target work priority area hour work million enable sustainable business performance fatality reduce reportable injury illness rate number injury illness lose time year end enhance ehs calendar day lose leadership capability engagement expand number injury illnesse lose time live safety improve driver safety programme losttime injury illness rate produce simplify ehs management tool hrs work risk reduction simplify ehs standard calendar day lose rate hrs work policy revise ehs governance structure reportable injury illness rate introduce predictive way reduce risk develop hrs work illhealth absence risk reduction strategy note behaviour value launch ehs datum cover employee contract worker directly engagement programme drive new ambition supervise gsk employee report snapshot injury illness performance year case add end year develop lead metric advance warning prior year change risk basis target set losttime injury illnesse workrelate injury illness include ehs culture index metric result day away work base near miss reporting prevent lose calendar day day include weekend employee incident work workrelate injury illness help provide measure severity injury illness eh operating model enhance ehs critical reportable injury illnesse lose time incident capability assess fill competency gap result time away work aid result lose time aim rapid adoption good practice increase global consistency identify read online address gap publish position online include hazardous chemical management gsk reach regulation wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report people community community investment community investment aim maximise benefit community investment respond japanese earthquake working partnership ngo select improve health education increase project enable use expertise resource follow earthquake devastating tsunami access medicine healthcare benefit community investment japan march gsk japan mobilise team strengthen business improve reputation orange employee volunteer deliver food service target support boost employee morale help build blanket face mask emergency product difference relationship base mutual understanding people colleague affect area tohoku range stakeholder district employee fundraising campaign raise support ongoing reconstruction approach include fund innovative programme programme support design long recovery effort improve health community engagement term sustainable impact set ambitious commitment behavioural change donate medicine expertise work experience partner contribute essential medicine gsk reinveste profit improve healthcare consumer healthcare product affect area infrastructure invest science education read health section report value million donate million cash support relief effort follow natural disaster include detail progress commitment japanese red cross respond quickly longterm albendazole donation programme sure minimal disruption target neglect tropical disease elimination product supply detail lymphatic filariasis know elephantiasis create orange scholarship fund treatment child intestinal worm support student affect earthquake reinvest profit develop thirty student study pharmacy university country ldc healthcare infrastructure tohoku start receive scholarship yen partner lead nongovernmental approximately month graduation organisation ngo address shortage train help continue study university frontline healthcare worker personal hygiene sanitation education phase programme run partnership ngo aim reduce diarrhoeal disease improve water quality encourage people wash hand encourage employee involve volunteer orange day pulse initiative read thesegsk corporate responsibility report people community investment performance community performance half cash give million target give health programme include partnership global community investment million amref care international save child support million overall giving remain constant training frontline healthcare worker cash exclude oneoff commitment reinvest profit product donation million dose vaccination develop country read inkind world health organization use develop publish datum charitable grant management country patient group grant online total value donation cost average cost good patient assistance program account wholesale acquisition cost wac measure half overall give read company believe detail factor impact accurate reflection true cost gsk belong programme expect breakdown cash give uks london benchmarking group lbg continue include removal committee encourage corporate philanthropy cecp brand medicine give commercial availability lbg guideline report product donation cost lowcost generic product fall patient enrolment health cecp guideline report product donation market change medicare switch education value benchmarking purpose report retail mail order reduce overall programme art culture wac value donation total value cost include figure environment global giving wac product donation ldc reinvestment million million participation pulse programme continue increase million invest pulse product donation cost million volunteer continue receive gsk salary main programme placement programme operating cost patient assistance program support lowincome represent million inkind donation help hero patient usa million begin investment olympicsrelate community humanitarian product donation million programme scientist sport personal well read donation albendazole tablet lymphatic gsk support new phoenix wellness filariasis elimination programme million viiv healthcare double give centre tedworth house personnel recovery million million drive assessment centre tidworth salisbury injure read policy principle underpin approach product donation online expansion patient assistance programme servicemen woman charity help continue fund paediatric innovation seed fund hero provide fund million positive action child fund read year support programme gsk corporate responsibility report people community feature bring science london olympic paralympic game excitement generate london olympic paralympic game opportunity advance scientific progress inspire new generation young scientist improve health wellbeing community employee achieve official london partnership go commitment create positive last legacygsk corporate responsibility report people feature bring science london olympic paralympic games community promote fair play advance scientific progress inspire young scientist improve health wellbeing community official laboratory service provider london inspire gsk create scientist london opportunity improve london game contribute expertise sport school outreach programme jointly develop health wellbeing community initiative research development support integrity kcl antidope ukad help personal good initiative nhs game health athlete scientist king year old understand role science play london help deliver health legacy london college london kcl use new world anti games excite potential science inspire million people aged doping agency wada accredit laboratory establish career child visit university participate longterm health condition lead gsk test use performanceenhance drug activity hear science sport active lifestyle game help recruit time run ukwide challenge motivate employee phd student support kcl antidoping school endorse british science association expert analyse sample london partnership team design portable antidoping kit test previous game gsk currently work recognise gsk employee positive difference test new substance develop kit secure sustainable future laboratory ticket allocation gsk science ambassador use outreach hope operate standalone business olympic paralympic game reward employee programme range free resource teacher game gsk select employee demonstrably live joint gsk olympic pupil available wwwscientistsinsportcom manage antidope control centre paralympic ideal integrity equality friendship ambition reach secondary school olympic paralympic venue athlete excellence thousand schoolchildren participate provide sample programme continue help fight doping game commit supply wada confidential information medicine early stage development potential abused athlete allow develop testing technique medicine market official laboratory service providergsk corporate responsibility report people community investment pulse employee volunteering community pulse employee volunteer month complete pulse nearly major volunteer programme orange day give volunteer say energise employee pay day year volunteer contribute time expertise money work gsk eightythree cent volunteer team choose local community project year thousands product create positive change community member gsk say pulse enable volunteer staff volunteer national day service operate volunteer programme share different external perspective help remembrance tenth anniversary pulse orange day provide employee inform shape gsk work think policy activity include pack meal opportunity impact develop ngo manager say people haiti kenya nicaragua flood victim knowledge capability volunteer impact sustainable month usa national day initiate mygooddee pulse give employee chance join nonprofit pulse assignment end charity found sponsor nongovernmental organisation ngo recent international corporate volunteering month fulltime placement enable employee benchmark study independent organisation leadership potential develop professional skill pulse emerge topofclass compare new challenging environment help partner international corporate volunteering organisation develop implement strategic plan programme pulse differentiate peer improve process operation enhance programme breadth scope duration communication marketing assignment incorporate rigorous process work pulse partner support measure impact partner organisation gsk organisation work healthcare education volunteer environmental issue area great need evolve programme launch prove track record start new partnership pulse pillar focus multiyear multi ngo include care international jen volunteer project strengthen contribution japanese emergency relief charity philadelphia area malaria access health child education fund pulse volunteer continue improve measurement help volunteer come country well understand impact pulse country nearly employee increase diversity pulse volunteer ngo pulse volunteer pulse partner country serve pulse volunteer participant continue support pulse organisation local hub japan establish pulse local hubs latin america indiagsk corporate responsibility report people case study community investment pulse employee volunteer community impact award annual impact award recognise small award open charity annual mediumsize charity provide excellent turnover million innovative local community healthcare million usa prize philadelphia raleighdurham region money impact assessment offer feedback usa advice winner help strengthen management plan step forward receive overall winner impact award charity provide win highly commend free confidential advice personal development organisation invite impact service disadvantage young people award development network set connect tower hamlet london winner receive win charity provide day include bryncynon strategy cynon organisational development training training valley wale develop innovative way fund host gsk facilitate king improve public health service deprive community fund year experience train senior affect loss local coal mining industry leader health sector usa awards give organisation year include housing new hope help homeless people access healthcare service integrate approach homelessness phoenixville healthcare access foundation assist uninsure underinsured lowerincome individual obtain dental vision prescription servicesgsk corporate responsibility report behaviour content introduction clinical research ethical conduct patient safety prevent bribery supply chain behave open corruption supply marketing product distribution process honest manner feature change supplier standard way incentivise performance sale team usa security supply publishing payment supplier diversity healthcare professional public policy publishing grant patient advocacy donation trade industry training awareness association monitor public policy activity compliance political contribution datum privacy lobbying expenditure research practice patient advocacy animal research human right build strong valuesbase culture recognise click arrow need section open challenge face action back robust policy strong compliance processesgsk corporate responsibility report behaviour introduction commitment responsible ethical conduct commit performance progress integrity building strong valuesbase valuesbase business underlie culture develop robust policy compliance develop new sale model decouple pay include process employ right people clear sale representative usa number stand help make prescription issue conduct report research ethical decision update global code practice promotion sale marketing practice customer interaction bring great consistency research practice investment core lobby policy activity operating practice company business essential meet consistently relationship supplier high ethical quality standard publication payment grant donation recognise aspect research healthcare professional organisation usa raise ethical concern aim open continue work disclosure set high standard employee address market policy compliance programme expect eache agreement principle standard supplier contractor supply chain effective responsibly manage government conclude number ongoing business partner importantly build supply chain essential provide medicine investigation sale marketing practice culture decision guide value product patient consumer aim settlement payment billion necessary transparency respect people integrity work responsible supplier set expectation step resolve longstanding matter patientfocus standard ethical conduct labour practice reflect company today protection human rights environment health safety management performance reduce number animal compare public policy patient advocacy develop new scientific engagement policy public policy activity support legislative measure standard reinforce clear distinction programme support scientific innovation balance scientific dialogue promotional activity interest business stakeholder ensure reflect value engage work patient professional group help member gain strong voice healthcare new commitment disclose result summarie human right commit uphold investigational medicine clinical study universal declaration human right core labour completion approval termination standard set international labour organization asset sign global compact aim act conduct clinical quality assurance assessment responsibly sphere influence include cover gsk external research carry employee supplier local community society behalf broadly improvement patient safety system database monitor gsk corporate responsibility report behaviour ethical conduct ethical conduct priority gsk prevent bribery corruption antibribery corruption programme audit pricewaterhousecooper conclude failure uphold high ethical tolerate bribery corruption risk area manage recommend standard erode trust clear prevent corrupt practice policy enhancement relate diligence code conduct performance review monthly procedure antibribery corruption training company product damage head governance ethic assurance programme implement recommendation reputation result legal department establish anti bribery corruption expert forum meet financial legal consequence week answer employee question advise employee read antibribery policy acces antibribery corruption issue member antibribery handbook elearne module code conduct set fundamental standard forum include representative antibribery intranet elearning training mandatory employee support employee guide corruption team legal compliance function manager employee work certain function business conduct available language help business representative minute meeting legal department region employee ethical decision emphasise distribute member forum high risk corruption supplement value transparency respect people integrity compliance officer convey key message face face train employee high risk role focus patient employee new guidance document create end employee take result issue discuss post training read antibribery compliance programme aim embe valuesbase intranet site employee visit corruption handbook online culture gsk launch compliance initiative improve consistency policy enhance screening process reduce introduce antibribery corruption audits implementation monitoring business bribery corruption risk associate use frequency timing determined regular unit different country operate party include distributor consultant risk assessment design provide assurance work gsk behalf market screen bribery corruption risk adequately include background check design identify manage policy procedure mitigate potential issue associate party high risk work effectively audits focus area risk category instance act behalf pose high risk bribery corruption perspective gsk interact government official include travel entertainment expense petty cash agree business issue raise use consultant screening address mean proceed propose relationship insertion additional contractual clause enhance monitor training partygsk corporate responsibility report behaviour ethical conduct marketing product marketing product global code practice promotion strengthen number commercial practice customer interaction policy usa include enhance oversight market prescription medicine vaccine review educational reprint publication healthcare reflect commitment consistently high standard healthcare professional hospital government economic information material sale marketing review update people concern marketing pharmaceutical promote medicine pharmaceutical business global code practice promotion customer company exert undue influence doctor sale introduce new policy governing support usbased interaction code cover area representative doctor information nonprofit healthcare organisation centralise provide information fee service payment product promote management funding support healthcare professional sample hospitality grant promotion medicine unapproved use exist donation roll publish directtoconsumer marketing policy update global code practice promotion website employee contact healthcare customer interaction forbid practice advertise prescription medicine directly professional include sale marketing staff unethical conduct reinforce policy consumer usa new zealand bangladesh train standard revise code training compliance procedure make sure south korea directtoconsumer dtc advertising way pay sale team reinforce value regional local policy standard operating prescription medicine permit market read remuneration sale team overleaf procedure code provide additional guidance promote use prescription medicine directly employee reflect difference regulation market recent year fundamentally change consumer subject criticism believe structure national healthcare system procedure compliance marketing sell responsible pharmaceutical advertising useful source stringent global code region usa ensure operate high standard health information patient help increase country restrictive review integrity conduct business openly knowledge condition educate patient update countryspecific code sure transparently reach agreement principle treatment option dtc advertising usa incorporate requirement new global code government conclude number ongoing review legal regulatory medical specialist practice promotion customer interaction investigation sale marketing practice new dtc television advertisement submit settlement payment billion final settlement strengthen standard govern food drug administration review corporate integrity agreement expect share scientific clinical datum medicine comment prior broadcast address civil criminal liability group develop available take decision stop television advertising sale marketing practice remain subject ongoing patient ensure clear distinction usa erectile dysfunction medicine negotiation expect finalise appropriate scientific dialogue legitimate promotional advertising legal decision significant step resolve difficult longstanding activity new standard introduce april long advertise medicine television legal matter reflect company refer scientific engagement impact respect viewer today fully commit ensure appropriate way engage scientific activity advisory promotion medicine standard rightly board publication scientific congress activity expect medical education read standard gsk corporate responsibility report behaviour feature change way incentivise sale team usa sale team play important role provide physician prescriber uptodate information safety benefit medicine vaccine information help doctor informed treatment decision patient critical representative line value put interest patient gsk corporate responsibility report behaviour feature change way incentivise sale team usa develop new sale model align new model incentivising sale representative change market expectation customer work directly healthcare professional aim example modify structure reward sale representative support sale team company customer need achieve well patient outcome decouple pay sale representative base bonus individual territory usa number prescription issue base sale goal instead measure performance individual sale target assess performance past multiple sale professional assign determine bonus factor sell competency different product physician health customer evaluation overall performance plan case person responsible sale professional business unit customer portfolio product bring specialist business need change align incentive value provide support transparency respect people integrity patient focus share information new model factor change align change healthcare include government environment usa physician practice hospital consolidate decisionmake europe change way reward increasingly centralised believe new approach pharmaceutical field sale staff replace individual sale assess performance sale representative put strong position meet great demand target basis reward qualitative criterion patient healthcare provider payer high overall business financial achievement individual quality care low cost well health outcome index performance measuresgsk corporate responsibility report behaviour ethical conduct publishing payment healthcare professional publishing payment begin sign statement training awareness number lead healthcare company healthcare professionals association british pharmaceutical industry training awareness programme help employee payment healthcare professional hcp abpi commit report payment annually understand importance ethical conduct help participate scientific conference speak aggregate level begin payment apply policy practice hire new meeting conference behalf gsk product cover payment healthcare recruit carry preemployment check ensure disease therapy area relevant sit professional speak advisory service share gsk value include question ethic provide expertise gsk advisory panel conduct sponsorship ukbased company use integrity guide gsk sponsor research service valuable basis global standard gsk employee interview business improve patient health gsk continue report payment name individual new employee complete induction training believe professional fairly compensate level usa gsk code conduct specialised training provide service expertise payment provide employee work manufacturing publishing grant donation excessive support sale market additional inducement reward prescribing product gsk regularly ask grant donation regulatory requirement commit publishing payment healthcare organisation support range activity example training include launch hcps usa payment hcp grant monetary contribution perform integrity programme new staff speak advisory service publish quarterly fund attendance organisation hcp usa quarterly train senior employee website quarter gsk medical scientific meeting cover expense lead integrity update coach pay healthcare professional total million support research support independent medical tool sale employee include question exclude research development payment fourth education programme donation nonmonetary value compliance help supervisory staff well quarter figure publish march contribution medical equipment textbook assess ethical behaviour sale team read commitment benefit patient healthcare organisation update personal development programme disclosure research payment healthcare separately community investment grant usa include performance development objective professional institution product donation include disclosure relate employee implement value commitment publish payment community investment grant require manager employee interact service grant donation healthcare patient advocacy organisation cover later healthcare professional confirm annually professional organisation outside usa section comply ethic policy certification process remain fully commit disclosing publish grant donation usa quarter supplement new training programme payment achieve challenging system website commit extend employee increase awareness introduce process country need aligned help grant donation outside usa align collate datum different system multiple currency disclosure grant donation outside work create introduce appropriate usa aggregate level time frame process ensure effectively disclosure payment healthcare professional accurately enable robust complete reporting outlined publishing figure grant consistently company take donation decision delay disclosuregsk corporate responsibility report behaviour ethical conduct monitor compliance monitoring compliance address misconduct believe increase see employee discipline introduction manager ensure compliance company contact attendance payroll category policy area responsibility corporate ethic compliance channel include attendance issue mainly report ethic compliance department monitor track enquiry request information guidance manufacturing business implement allegation suspect legal ethical policy infraction allegation misconduct line manager tight control ensure maintain build ensure allegation appropriately investigate compliance officer confidential reporting line strong track record compliance additionally disciplinary action include dismissal offsite post office box usa continue focus manufacturing quality see report relevant external authority take increase disciplinary number necessary violation policy employee discipline policy violation good manufacture practicegood distribution report audit risk committee board practice gmpgdp category time period dismiss agree leave expand network compliance officer company voluntarily know separation category remain broadly consistent deputy compliance officer business unit time disciplinary action include document region role closely align warning type policy violation business work identify monitor business product specific risk early strategy disciplinary action include case phase work mitigate risk outset project employee breach sale marketing code attendance payroll increase independence compliance team case result seven dismissal separation gmpgdp compliance officer fund report directly company remain case result falsification document corporate ethic compliance department document warning code conduct local business unit addition appropriate discipline employee stay marketing employee encourage seek help ethical issue company receive retrain increase promotional activity report concern suspect case misconduct monitor case retrain extend policy violation line manager corporate employee colleague prevent make total violation ethic compliance department compliance officer similar mistake gmpgdp relate good manufacturing practice compliance champion gsk human resource legal good distribution practice department global confidential reporting line integrity helpline global confidential reporting line available different languagesgsk corporate responsibility report behaviour ethical conduct datum privacy breach external code datum privacy plan collect information centrally breach external datum protection security continue high compliance initiative industry government promotional code priority gsk establish global privacy establish compliance advisory service advise commercial business breach define sale principle ensure personal datum collect senior leader business risk associate marketing infraction violation law obligation process transfer store appropriately emerge business strategy responsible code standard result fine censure gsk securely line legal requirement promote valuesbased compliance culture government agency industry association breach create global privacy office oversee privacy business enhance compliance usually available publicly industry group regulator process communicate good practice gsk operation function investigation capability website publish local news medium continuously improve compliance effort began implement bind corporate rule find breach external code time standard datum privacy improve efficiency pharmaceutical business create time include transfer personal datum company implement control centre excellence breach country specific regulation code increase confidence security personal datum ensure alignment compliance majority relate new consumer product entrust bind corporate regulatory requirement company policy marketing promotion regulation introduce rules european commission approve approach mitigate risk enhance governance address current local ministry health enable company transfer personal data affiliate anticipate need effort drive accountability locate outside european economic area compliance businessdriven control centralise monitor inappropriate promotion pharmaceutical product european data protection regulation report support business build enhance relate strict regulation bind corporate rule cover personal datum hold control capability advertising material promotion pharmaceutical employee research subject healthcare product local operating company professional partner research adhere read online epsilon marketing service supplier fully investigate breach external code target malicious attack customer code conduct step prevent reoccurrence personal datum steal include name email include retrain corrective action include address gsk company affect mployee guide business conduct disciplinary action aim continually improve security breach ntibribery corruption programme handbook process ensure compliance industry code ntibribery corruption programme party government regulation data breach incident response team assess guideline situation notify gsk consumer affect email day incident set hotline sk prevent corrupt practice policy question complaint advise consumer gsk marketing practice lookout unusual suspicious email wwwgskcomresponsibilitygsk corporate responsibility report behaviour research practice essential meet consistently ensure apply recognise standard principle animal research good medical science integrity ethic discovery high ethical quality standard development marketing gsk product animal study remain small vital research development system principle policy accountabilitie know research case method medical governance framework ensure demonstrate effect potential new part business medicine living body test human patient safety fundamental operating principle country operate animal research provide vital information ahead commercial interest cause disease disease develop research conduct objective scientific safety regulation require test new medicine patient safety priority evaluate ethical manner protect inform patient animal evaluate clinical trial benefit risk medicine stage research prescriber payer country require additional animal testing new product approve sale promotional practice information provide market medicine commit transparency disclosing result product ethical accurate balanced approve use clinical research meet legal regulatory obligation animal necessary research recognise aspect research support appropriate use product maximise commit act ethically provide animal raise ethical concern include relate benefit minimise risk patient health wellbee practise good animal animal clinical research use emerge welfare principle apply study technology aim address concern overall responsibility framework sit carry gsk facility conduct open approach regularly engage chief medical officer support medical external contractor behalf academic scientist regulator policymaker governance board business ensure stakeholder consistent operation medical governance develop new gsk policy guidance ultimately gsk like important benefit clear accountability reenforce clear distinction research apply human need scientific engagement product promotion animal testing believe achieve foreseeable future goal use animal scientifically necessary use scientifically guide research understand unmet feasible minimise pain distress medical need patient focus daily work meeting need focus patient scientist apply principle replacement programme help bring patient reduction refinement biomedical research gsk site speak directly team replace animal research method specific healthcare need read possible programme reduce number animal provide information give precision refining technique minimise pain distress maximise animal welfaregsk corporate responsibility report behaviour research practice animal research encourage culture gsk regular training performance change number animal gsk staff involve care use animal raise number animal lower compare key driver animal use awareness encourage good practice recognise main driver animal use employee significant advance investment vaccine sale increase implement animal welfare award period progress animal use decline compare faulty gene cause contribute number continue yearonyear decrease potentially fatal illness cystic fibrosis reflect number factor include change research form motor neuron disease valuable method priority few vaccine require testing animal understand potential treatment genetic batch release continue focus initiative disorder involve make small change responsible animal research conduct contractor behalf animal gsk facility gene rodent scientist model account total animal use animal contractor behalf gsk human illness examine change investment plus vaccine sale animal gsk research include experimental medicine affect development research carry contractor rodent mainly control condition process lead investment plus vaccine sale main driver animal use rat mice nonrodent account figure normalise year datum formation birth animal carry modification number animal glaxosmithkline datum include animal research conduct external suitable research contractor behalf datum unavailable animal use nonhuman gsk scientist develop method sample primate number decrease onehalf specie gsk animal research screen dna sperm mouse determine voluntary commitment mouse carry desire modification mean long perform research great ape male mouse likely pass require gene fish select breeding lead future strategy group programme rabbit approximately reduction number animal examine approach conduct animal dog breed achieve stable genetically modify line research global basis team draw view nhp team carry share work stakeholder include welfare organisation ferret peerreviewe scientific publication regulator integrate strategy propose focus farm presentation conference deliver high quality science reliance bird animal include building commitment animal type biomedical development innovative alternative animal mouse research rodent majority mice detail find publish position online research optimise animal study enhance rat scientific review find way maximise harness guinea pig use research datum bolster external collaboration area strategy endorse rodent wilson sheardown transgenic re apr approve global implementation nhp refer nonhuman primate farm indicate use pig goat sheepgsk corporate responsibility report behaviour research practice animal research strategy global governance advocacy animal principle scientific engagement research responsibility office chief animal welfare veterinary medicine essential research principle scientific channel provide strict separate department responsible product meet need engagement adopt framework engage stakeholder daily care animal accountable deliver patient reflect late reinforce commitment group include healthcare objective identify future strategy group scientific thinking achieve intent action professional payer patient assess core principle development medicine scientific engagement advocacy medium animal research need research review carry discussion stimulate accelerate demand focus scientific engagement ethical review panel apply worldwide exchange scientific medical gsk product gain favour result change find high level consistency topic information gsk prospective prescriber way work example local committee look review process outside expert stakeholder customer principle ensure strengthen medical agree supplementary principle help local ethical help ensure research gsk value transparency accountability governance review group apply policy practice include add scientific understanding integrity respect patient focus scientific engagement activity composition ethical review panel use train advance care patient underpin intention action appropriate ensure competent personnel evaluation alleviation important scientific engagement govern budget activity reside pain distress legitimate scientific engagement way engage publish medical function example see gsk animal research laboratory europe asia science scientific literature change postpone promotional intent north america aim achieve present science scientific disease awareness activity accreditation association assessment develop new gsk congress seek gain advice product development accreditation laboratory care aaalac international policy standard reinforce external stakeholder provide product authorisation achieve accreditation facility hungary clear distinction scientific medical information answer firmly believe scientific france sirtris facility usa aaalac dialogue promotional activity unsolicited question engagement fundamental gsk accreditation cover animal house new standard introduce product provide support develop medicine value gsk facility april call scientific medical education scientific patient strengthen engagement govern engagement policy area standard ongoing way engage scientific govern approach commitment continually evaluate activity advisory board product gain necessary conduct business publication scientific congress authorisation approval ensures reflect gsk value medical education addition approach scientific engage stakeholder engagement prior product include healthcare professional authorisation cover congress physician payer patient sponsorship digitalgsk corporate responsibility report behaviour research practice clinical research clinical research use variety procedure protect confidentiality work healthcare professional research participant datum ensure conduct clinical research clinical trial healthy volunteer patient enable individual identifiable medical datum keep securely assess investigational medicine potential protect inappropriate use disclosure read gsk conduct clinical trial work healthcare evaluate medicine approve approach privacy professional act investigator study market conduct clinical trial accordance policy require clinical trial investigator good clinical practice gcp guideline develop recognise ongoing treatment clinical trial select solely qualification conduct good international conference harmonisation participant medicine end trial quality clinical research history principle contain world medical association require continued care patient gsk product take account declaration helsinki ethical principle general responsible funding payment govern contract compensation medical research involve human subject medicine trial responsibility reflect fair market value work perform government provider national trial protocol review ethic committee healthcare system begin trial service provide payment offer independent gsk member disease condition continue influence investigator judgement enrolment public medical professional scientist ethic completion trial assure maintenance research participant clinical study committee power reject stop clinical trial healthcare system able provide gift permit healthcare professional involve research project gsk conduct clinical trial country responsibility continue care patient know outset intend pursue exceptional specific circumstance provision commitment disclose research payment registration product available use medicine fund gsk trial healthcare professional institution country gsksponsore clinical trial conduct read policy clinical trial annual disclosure usa ethical standard irrespective develop world online capture payment phase medicine discovery place require contract research organisation development include clinical trial carry trialrelate activity behalf meet website detail outside usa disclose standard payment healthcare professional research institution aggregate basis commence safety clinical trial participant paramount publication payment read importance evaluate safety phase clinical trial programme potential clinical trial participant voluntarily confirm willingness participate informed study benefit risk know informed consent aim provide information potential trial participant nontechnical style lie person understand review update informed consent form clear patientsgsk corporate responsibility report behaviour research practice clinical research training auditing clinical trial addition investigation conduct response public disclosure clinical research suspect irregularity investigator site cro employee involve gsksponsore clinical research gsk commit public disclosure clinical local operating company gsk fully investigate receive train good clinical practice gcp research evaluate investigational authorise concern issue identify take corrective employee complete require training medicine irrespective result perceive action appropriate corrective preventative undertaking role relate clinical research positive negative medicine believe action include example retrain increase gcprelate training activity fundamental advance medical science monitoring case significant persistent non represent successful completion elearning inform prescriber patient scientific finding compliance identify impact module instructorle course relate medicine commitment addition patient safety integrity datum severe action legal regulatory requirement disclose relevant risk management compliance framework include include termination activity report datum clinical trial safety information independent audit assessment conduct regulator take regulatory authority clinical trial audits assessment cover gsk system regulatory authority perform inspection process external contract research disclose result research publicly gsk investigator use conduct clinical organisation investigator conduct clinical accessible clinical study register website launch trial research behalf report audit result quarterly receive average visitor month compliance board annually risk gsk complete compas trial clinical otitis database register require law oversight compliance council audit medium pneumonia study argentina assess regulation clinicaltrialsgov usa risk committee gsk board director efficacy pneumococcal vaccine synflorix january information available gsk site include protocol trial subject medium coverage summary ongoing study summary conduct clinical quality assurance administrative conduct trial result complete clinical study read assessment example position disclosure clinical trial information online investigator site conduct gsksponsore clinical regular monitoring identify trial represent site provide administrative error process obtain primary datum regulatory approval base inform consent small proportion study number result summary gsk clinical trial gsk process include process review participant proactively report national gsk clinical study register regulator immediately corrective action plan clinical trial imaging datum process management human biological sample place trial centre doctor involve number summary cumulative total time safety participant risk contract research organisation cro carry regulator agree trial continue plan clinical trial gsks behalf conduct clinical trial high standard gsk local operating company involve clinical irrespective world run trial activity include requirement obtain inform consent new drug application nda annual report participant fundamental principle review prior submission food drug behaviour continue actively review procedure administration fda provide update ensure good practice minimise risk status study complete progress error occur future gsk corporate responsibility report behaviour research practice patient safety change policy timing patient safety improvement innovation disclosure clinical research medicine previously aim disclose result summary trial patient safety priority evaluate continue improve patient safety system investigational medicine time approval benefit risk medicine medical device safety database monitoring process example follow termination investigational medicine stage research new product change approach disclose result approve sale develop enhancement enable rapid review safety follow completion study follow medicine potential risk benefit information observational data source approval termination medicine take medicine work regulatory agency observational gsk commitment seek publication experience effect important identify medical outcome partnership omop publicprivate result clinical research evaluate evaluate minimise safety concern ensure partnership understand well detect safety issue medicine paper peer review scientific overall benefit medicine outweigh risk establish system provide realtime alert journal publication provide peerreviewe context product safety assess clinical trial product sudden change number adverse event report interpretation research datum put approve marketing adverse event receive month particular product place system resource meet commitment possible effect detect approval create pharmacovigilance centre excellence product large number patient refine approach medicine safety commit disclose protocol policy governance framework place help study study publish paper detect act adverse event dedicated team new capability scientific literature interested party scientist healthcare professional world gsk commit provide transparent information research carry specific role monitor communicate safety health issue patient healthcare provider issue regulatory authority work importantly gsk policy prohibit ghost write regulator example establish new team government official industry partner policymaker journal manuscript require authorship focus clinical effectiveness gsk medicine enhance safety system medicine vaccine acknowledgement scientific publication assess benefit risk development consistent requirement international global safety board make decision product postapproval period gsk group work committee medical journal editor guideline safety issue remit ensure safety focus advance capability internally externally product development review safety goal new team achieve great integration gsk product market board chair effort allow well evidence chief medical officer compose senior clinical comparative effectiveness medicine physician scientist build strong regulatory file inform physician regulator payer value medicinesgsk corporate responsibility report behaviour research practice patient safety collaboration patient safety benefitrisk management adverse event report gsk record work government official industry partner global safety database clinical trial database assess balance benefit risk policy maker enhance safety system medicine investigate report potential safety concern particular medicine lifecycle early vaccine example global regulatory authority regulator country development clinical research product collaboration include publish information adverse event internet market available safety information evaluate cofounder international adverse document build detailed benefitrisk profile respond adverse event event consortium isaec nonprofit collaboration product use information develop benefit adverse event affect benefitrisk profile partner include pharmaceutical company risk management plan identify way improve product corrective action need minimise academic institution regulatory body product benefit minimise risk plan review risk include carry additional clinical working improve patient safety identify genetic update regularly clinical development research understand concern modify variant predict adverse event isaec initial period product approve marketing prescribing information communication research focus druginduced liver injury collecting report safety datum physician healthcare provider druginduce skin rashe globally establish specific method minimise risk receive information adverse event possible agree definition druginduce liver injury example highlight warn prescribing effect source include patient analysis drug associate skin information product subject limited healthcare professional regulatory authority post toxicity publish distribution programme prescription specialist marketing clinical research gsk staff undertake participation critical path institute mandatory training adverse event report doctor certain case appropriate stop predictive safety testing consortium independent require immediately report issue relate clinical trial withdraw product market nonprofit organisation bring scientist safety quality medicine read global specialist committee review approve industry academia share validate expectation code conduct prescribe information medicinal product safety testing method guidance ensure update appropriate food drug administration fda european medicines agency ema study share new read online way predict safety issue clinical trial post marketing publish share clinical trial develop world european regulator clone technology stem cell research disclosure clinical trial information care welfare treatment animal role transgenic animal biomedical research aithal case definition phenotype standardisation nonhuman primate nhps discovery druginduce liver injury clinical pharmacology therapeutic development medicine vaccine papay spontaneous adverse event report steven johnson syndrometoxic epidermal necrolysis detect association wwwgskcomreportsandpublicationspolicie medication pharmacoepidemiology drug safety article publish online dec gsk corporate responsibility report behaviour supply chain patient consumer rely manufacture division strong track record finalise agreement quality compliance current good manufacturing government respect investigation provide uninterrupted practice cgmp requirement commit process negotiate corporate integrity agreement supply medicine product continuous improvement manufacturing process cover manufacture compliance matter year invest million improve second warning letter issue manufacture high updating equipment average concern manufacturing standard worthe facility quality standard inspection regulatory agency year impact manufacturing suspend additional manufacturing site locate country control implement production effective responsibly manage supply food drug administration fda resume patient consumer quality distribution system essential highquality warning letter cgmp deficiency product priority product right place right time year glaxosmithkline form concern people health suffer life manufacturing issue cidra facility risk protect interest patient fully resolve site close consumer aim work responsible supplier decline demand medicine meet quality social environmental standard gsk human right supply chain gsk strive conduct business consider human right issue knowingly use supplier thirdparty supplier routine interaction responsible human right share commitment high critical supplier environmental infringement identify ethical standard operate health safety audits potential human right issue responsible ethical manner new exist critical supplier recommendation include question help supplier improve performance human right clause include identify potential breach followup supplier contract cover human right clause supplier significant gap party code conduct ask information policy available online include member practice relate limited force labour pharmaceutical supply chain child exploitation slavery workplace age limit employee initiative psci industry condition non discrimination discrimination employee collaboration set guide wage benefit work hour local population principle standard supplier read human right statement prevention abuse individual include human right online information labour issue psci look wage benefit work hour clause include contract way improve supplier standard right worker organise especially emerge market recognition worker organisationsgsk corporate responsibility report behaviour supply chain supply distribution process supply distribution process make product require ingredient supply distribution process material buy supplier feed interest patient consumer come ensure continuous supply network manufacturing site country stage supply distribution process highquality medicine manufacture nearly gsk product produce plan essential patient plan involve decision approximately billion package annually include consumer depend deliver entire lifecycle product help tablet cream ointment inhaler injection product configure location capability capacity liquid people work global success business network internal thirdparty manufacturing site manufacture supply gms division spend billion order maximise efficiency security supply outsource term production cost supplier billion ensure continuous supply highquality medicine product manufacture thirdparty manufacturer material directly require vaccine consumer healthcare product essential provide finish partfinishe product buying manufacture patient consumer depend product responsible manufacturing require product product spend success business consistently supplier high quality country worldwide buying involve gsk spend billion supplier billion spend distribute product rely work people active ingredient chemical intermediate package company ship customer country work manufacturing component material directly require product stored correctly handle carefully supply division manufacture product spend distribution point destination make site country supplier country worldwide depend ensure patient consumer benefit nearly supplier consistently deliver value low cost product protect reputation provider gsk product produce produce good responsible manner highquality effective medicine vaccine consumer billion package annually support impartiality phase procurement healthcare product cycle standard payment term supplier supply product mean protect ship product minimum day receipt invoice customer country distribution system disruption establish ensure product store maintain contingency stock active pharmaceutical distributing correctly handle carefully regional distribution total spend supplier ingredient finish product important distribution product especially medically critical product destination regularly assess supply chain risk europe appropriate ensure key raw material work protect ingredient alternative supplier necessary asia pacific distribution system wrong possible ramification africamiddle east disruption maintain health wellbee customer supply latin america contingency stock regularly assess supply japan chain risksgsk corporate responsibility report behaviour supply chain supplier standard supplier standard high risk supplier identify assess gsk support supplier improve standard identify supplier require engagement supplier expectation standard ethical monitoring high risk supplier identify base work supplier improve standard conduct labour practice protection human right critical supply chain risk example ehs management system interaction gsk pose business fail meet standard audits identify number significant supply employee define party code person responsibility gsk relationship interruption risk risk life safety conduct code require supplier embed supplier ensure potential risk indian supplier multiple ethical standard supply chain supplier appropriately manage work supply agreement escalate gsk require new supplier accept comply procurement colleague internal audit investigate result restrict supply arrangement principle code business concern procurement risk integrate gsk supplier provide evidence environment gsk overall risk management compliance oversight process health safety manage responsibly code update strengthen problem supplier work significant risk effectively manage reflect requirement bribery act improve situation possible supplier working address concern issue guidance employee change add intractable difficulty end relationship improve process control additional clause antibribery corruption carry indepth audits contract template purchase order term audit supplier critical supplier europe india condition believe policy process focus specific key risk review ensure respect human right outline report select new critical supplier governance risk management process align requirement california pivotal business conduct audit enable build close productive transparency supply chain act come environment health safety performance risk relationship supplier agree plan effect begin system audit tool include question help improvement help mitigate risk assess potential supplier performance work supplier extend approach human right clause include supplier contract critical supplier new supplier require meet expectation party code conduct outline identify significant gap supplier policy procurement team engage exist supplier system performance number raise awareness code reinforce ethical course action recommend use external principle procurement staff procurement consultant support supplier make improvement responsibility receive training thirdparty management andor suspend restrict supply significant include supplier compliance human improvement case stop right standard ethic training employee work supplier decide work cover standard supply chain potential new suppliergsk corporate responsibility report behaviour supply chain performance collaborate industry performance supplier ehs audits pharmaceutical supply chain initiative psci exist potential supplier supplier information need meet industry conduct environment health safety eh expectation labour ethic environmental audits exist potential supplier health safety management system psci audits assess supplier asia americas member develop guideline tool significant ehs audit finding supplier europe mechanism enable shared approach audits occur mainly emerge market include asia pilot audit propose deficiency fire risk management emergency africa quality audits response capability absence fundamental risk total number audits control process safety inadequate control exposure conduct audit quality standard new hazardous substance inadequate waste management manufacturing material supplier environmental control gap compliance number type supplier audit ehs quality audits perform gsk material supply regulation potential new exist potential supplier chain supplier provide ingredient form supplier audit fail meet product take coverage quality audits minimum requirement type supplier america europe asia total manufacturing material supplier company primary raw material audit approve gsk supplier find gap risk consider extent intermediate approve provide meet certain condition number action include pharmaceutical ingredient restrict supply significant improvement contract manufacturing work number key supplier potential new supplier work pharmaceutical develop quality improvement plan design bring supplier ensure investment address formulation standard gsk expect deficiency provide finding help consumer healthcare work educate supplier quality requirement excipient active supplier improvement continue training session take raw material place nigeria south africa china indonesia pakistan india philippines gsk industry consortium agree sectorwide standard quality audits product ingredient supplier mean supplier number company audit multiple time result share purchasing company quality audits environment health consortium begin audit supplier behalf manufacture safety audits current member yearend carry audits material supplier potential supplier finding noncriticalgsk corporate responsibility report behaviour supply chain security supply security supply anticounterfeite gsk train local staff spot report counterfeit product invest measure find ensure continuous supply highquality medicine estimate onethird medicine vaccine serial offender analytical support team vaccine consumer healthcare product essential healthcare product part world example trialling test use vapour health depend product counterfeit counterfeit certainly fake toothpaste link counterfeit sample find success business support quality control testing monitoring world counterfeit manufacturer later contain little legitimate active significant threat security supply identify mean gsk able provide ingredient need include impurity earthquake tsunami japan evidence scale scope illegal activity colourant microorganism mean hour mobilise gsk crisis response team hopefully result stiffer penalty patient country receive despite difficulty affect communication air treatment need bad take found member pharmaceutical security freight road traffic able monitor supplier substance actually cause harm institute psi gsk work closely wide japan provide material gsk site counterfeit pose threat patient consumer pharmaceutical industry investigate case worldwide total material go stock health business threat gsk counterfeit government supply site able ensure pharmaceutical company international organisation gsk team work disruption patient business investigate suspect incident counterfeit minimal use anticounterfeite packaging feature gsk product conduct forensic analysis initiate legal hologram security seal complex background action offender pattern difficult counterfeiter photocopy scan read pilot anticounterfeite programme conduct text message ampiclox antibiotic nigeria partner supplier crisis major fire damage situation good example equipment transfer factory own key strong partnership supplier alternative factory gsk supplier march supplier benefit company site thirdparty continuity supply gsk manufacturer hour start product risk launch fire crisis management team work able schedule new antiepileptic gsk expert supplier maintain supply medicine medicine trobalt set patient minimise disruption jeopardy good product plan place impact business work relationship resume production quickly supplier potentially disastrous possible product andgsk corporate responsibility report behaviour supply chain supplier diversity supplier diversity work business advocacy organisation gsk anticounterfeite activity national association veteran business owner small company own woman people national minority supplier development number belong minority group council women business enterprise national report case represent supply chain large company council identify develop small diverse business counterfeit gsk believe small diverse business supplier particularly development number raid significant potential meet procurement need mentor initiative number arrest recognise value bring community global supplier diversity initiative outside usa case include work indian police job creation revenue generation source include sponsorship global link programme raid factory near delhi make counterfeit diverse supplier benefit gsk help help diverse supplier world develop version children medicine calpol lead comply regulation market usa partnership local business expand arrest raid carry pakistan result encourage innovation expose new perspective capabilities access new technology seizure different type counterfeit fresh idea supplier diversity programme lead target effort south africa usa support procurement medicine number arrest raid team worldwide counterfeit factory china help chinese police conclude longterm investigation usa finding challenge identify small raid counterfeit factory fuyang city diverse business fulfil federal size standard guangdong province yongcheng city henan time enable reduce cost consolidate province counterfeiter arrest global supplier spend small diverse supplier counterfeit medicine value million rmb decrease plan seize network shanghaibased counterfeiter increase spend small diverse business sell product internet break counterfeit problem emerge market read online usa offender sentence seven year prison order pay gsk read standard compensation find pack party code conduct weightloss treatment alli sell ebay contain dangerous level control substance sibutramine antibribery corruption programme oneyear sentence fine hand party guideline pharmaceutical importer raid premise human right statement include clause uncover pack illegally import seretide supplier contract place counterfeit packaging gsk counterfeit healthcare product wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report behaviour public policy patient advocacy public policy activity lobby public policy activity conduct industry association membership include external affair team major region pharmaceutical industry organisation association support legislative measure business unit monitor propose legislative reform british pharmaceutical industry abpi european programme encourage scientific policy development stakeholder concern meet federation pharmaceutical industry association regularly government official efpia international federation pharmaceutical innovation balance interest multilateral organisation ngo explain view manufacturer association ifpma japan business public policy issue respond directly pharmaceutical manufacturers association jpma gsk ask comment lobbying issue affect organisation pharmaceutical producer india oppi stakeholder work pharmaceutical consumer healthcare pharmaceutical research manufacturers america patient professional group industry conduct trade association phrma chinas rdbased pharmaceutical association help member gain strong hire lobbying consultant support committee rdpac public policy work voice healthcare consumer industry organisation european brands trade industry association association aim association european self medication industry aesgp european cosmetic recognise stakeholder concern gsk member national regional association colipa union european soft business lobbying aim address international trade industry association membership drink association unesda open approach issue engage group help support efficiency effectiveness public policy work general industry organisation intellectual property owner association ipo international chamber important lobbying trade industry commerce icc national association manufacturer association reflect policy value work nam confederation british industry cbi member set policy attend industry association meeting government gsk chief executive sir andrew witty currently stakeholders association adopt public policy president european federation pharmaceutical position agree participate industry association advocacy activity relate subject raise concern particular advocacy position directly association management teamgsk corporate responsibility report behaviour public policy patient advocacy public policy activity public policy activity europe healthy age initiative european congressional leader adopt mandate rebate union set pilot publicprivate partnership medicare consider similar believe conduct advocacy work active healthy age aim increase proposal come year continue look responsibly valuable contribution debate average number healthy life year chief way trim federal budget usa gsk issue impact business work balance executive steering group partnership industry partner analyse new proposal interest business stakeholder january gsk submit proposal action available continue provide information engage wide range issue world support initiative encourage great lawmaker importance maintain patient include healthcare reform pricing adherence prescription elderly people access innovative pharmaceutical product vaccine intellectual property issue vaccination elderly proposal patent litigation europe discussion continue adherence prescription action year particularly challenge public policy propose introduction single commission agree pursue implement perspective healthcare reform major market european patent centralise court patent gsk ask lead action austerity measure implement litigation gsk support principle single patent proposal support comprehensive country arise economic crisis recognise potential way reduce cost obtain vaccination programme elderly people need economic responsibility argue maintain european patent provide quality discuss approach costcutte measure achieve judicial process consistently high order appropriate balance manage cost medicare usa involve support concept centralise court incentivising innovation interest patient defend medicare federal prescription drug dispute european patent resolve payer industry insurance programme medicare beneficiary wide basis timely costeffective manner gsk federal lawmaker propose pharmaceutical discuss reform project year example provide insight approach industry pay mandate rebate medicare european commission area focus way reduce annual budget deficit usa continue involve healthcare reform usa gsk industry partner phrma wake passage affordable care act oppose proposal gsk submit comment number propose fundamentally alter success medicare regulations healthcare reform implementation competitive marketbase structure supportive act goal increase access health gsk meet federal lawmaker raise awareness insurance million americans success medicare explain current support provision law expand access programme result reduce healthcare preventive service promote development cost example study journal american valuebased care delivery model accountable medical association find improve access care organization patient center medical home adherence medicine result save believe reform implement way medicare year hospital nursing home recognise role medicine vaccine cost elderly person previously reduce healthcare cost improve health outcome lack comprehensive prescription drug coverage patient reduce prevalence costliness billion year saving medicare chronic diseasegsk corporate responsibility report behaviour public policy patient advocacy public policy activity support regulatory cooperation tobacco dependence cessation encourage oncology drug parity insure cancer patient european union china chinas regulatory government ensure national smoking usa high outofpocket cost environment pharmaceutical evolve cessation strategy provide smoker great support prescribe oral anticancer drug cover drug increase cooperation european union motivation stop gsk sell tobacco cessation benefit versus intravenous medicine cover china issue gsk believe strong product nicorette niquitin provide financial medical benefit disparity lead treatment regulatory environment china align support smoke free partnership sfp decision base dosage form international standard protect interest organisation aim promote tobacco control appropriate clinical option patient patient pharmaceutical company example policy research european national level thank talk patient organisation legislator current regulation company require gsk grant sfp develop smokefree policy importance eliminate cost disparity repeat china clinical trial new vaccine map europe oral oncology medicine state adopt approve marketing oncology parity legislation well oral health europe oral disease remain delay registration vaccine china major public health challenge europe represent pricing saudi arabia saudi arabian delay chinese patient access potentially annual public health spending estimate government reform legislation govern pricing lifesave product vaccine available cost member state billion year sponsor pharmaceutical product gsk believe support european commission new platform well oral health europe joint transparent easily understand system pricing efpia cooperation china issue initiative european association dental public need create stability marketplace help include support workshop increase health association dental education improve access medicinesany new legislation cooperation clinical trial quality control europe raise awareness oral health issue support swift introduction new innovative way forward foster innovation competitiveness link overall health lobby common product reward innovation treat local trade hold euchina highlevel regulatory approach european oral health policy multinational company equally work meeting devote pharmaceutical vaccine issue trade association advocate consultation anticounterfeite europe continue propose change sure new advocate paneuropean serialisation system system meet saudi healthcare need address noncommunicable disease member medicine believe need reduce long term need sustainable pharmaceutical international federation pharmaceutical manufacturer opportunity counterfeit medicine enter industry focus specific issue association helped develop point framework supply chain introduce paneuropean system proposal impose significant price action industry noncommunicable disease enable pharmacist europe check discount patent product produce advance september united nations summit pack dispense multinational generic medicine issue help detect counterfeit produce local company patent reform usa lobby support fast patient access medicine taiwan america invents act patent reform legislation work regulatory health authority shorten law believe modernisation time take new medicine market patent trademark office uspto necessary example speeding process agree create predictable equitable efficient patent system reimbursement price establish fair reasonable boundary challenge patent uspto courtsgsk corporate responsibility report behaviour public policy patient advocacy political contribution lobby political contribution lobbying expenditure usa spend federal lobbying activity include cost salary gsk corporate political contribution benefit employee register lobby usa employee choose personal government use lobbying consultant support political contribution gsk political action lobby contact planning activity committee pac facilitate voluntary political research run gsk washington government contribution eligible employee accordance affair office support staff portion trade federal election campaign act association fee associate federal lobbying gsk employee pac contribute report state lobbying expense line republicans democrats applicable state law unaffiliated party candidate run state federal office contribution policy group cost associate lobby institution gsk contribute group provide forum range declare policy analysis debate include think tank commission european parliament number country certain group usa voluntary register interest representative organise section include run brussels advocacy office internal revenue code gsk require salary external event travel accommodation recipient organisation usa agree refrain consulting cost educational material figure gsk fund support oppose federal state take account proportion employee time local candidate political office spend represent gsk interest order avoid read online double reporting register figure exclude trade association membership fee responsibility declare lie respective organisation publish position key issue online include ublic health access healthcare develop country price reimbursement market access conduct research development antibribery corruption programme approach intellectual property counterfeiting healthcare product environmental sustainability wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report behaviour public policy patient advocacy patient advocacy patient advocacy set advisory board usa launch minimum standard work europe include representative wide range patient group europe end help ensure patient group nonprofit organisation found patient group allow access views engagement patient group prioritise patient caregiver family member health patient group subject clinical trial underscore commitment patientcentric professional important stakeholder gsk pharmacogenetic information provide patient company example new standard state engage healthcare provider government ethical issue general manager country meet minimum medium patient promote improved treatment number patient group year employee service patient campaign issue engagement design market product train work highest ethical affect patient caregiver live include increase strict rule promote gsk standard patient group access quality medicine service information medicine patient group seek endorsement disease carry research cause medicine patient group aim usa advocacy alliance development center potential treatment specific condition transparent possible work excellence coordinate engagement funding funding provide publish information website patient advocacy group professional association provide fund patient group help dayto national regional state level coordinate standard work patient group day run cost define event activity approach particularly important period support include educational assistance training gsk employee relevant party work significant healthcare reform center staff collaboration disease awareness patient group follow guideline establish state advocacy team include team prevention project standard operating procedure sop example fieldbased staff cover state broken limit funding provide region relationship patient group help well patient group overall fund state relationship understand patient need illness guide plan extend guideline emerge market patient group link promotion turn support help patient opinion asia pacific region future product provide training employee hear healthcare debate understand requirementsgsk corporate responsibility report behaviour public policy patient advocacy patient advocacy workshop educational support patient advocacy leader summit european patient academy therapeutic innovation gsk hold regular workshop patient group patient advocacy leader summit pal bring feature session help patient adhere patient advocate discuss health policy issue patientle consortium fund european drug regimen improve treatment outcome develop new skill way expand influence commission trade association efpia working example session include additionally pal strengthen patient advocacy create european patient academy therapeutic workshop patient group representative organisation educate advocate create connection innovation eupati educate patient european breast cancer coalition europa donna building network patient advocate organisation representative thing design independent cancer patient voice manage improve health community conduct clinical trial drug safety riskbenefit effect oral cancer drug metastatic usa implement new approach pal assessment patient involvement drug development breast cancer provide engagement local gsk industry partner eupati contribute workshop adherence oral cancer treatment level include series regional pal rpal expertise staff time funding project regimen european patient group hold state focus aspect healthcare start february meeting members lupus europe umbrella reform introduction state health insurance eupati provide educational organisation national lupus selfhelp organisation exchange hold event patient group material european language target european understand need patient lupus washington explore role national advocate country aims release good practice dialogue patient healthcare professional implementation healthcare reform guideline patient involvement hold improved lead well treatment outcomes europe hold pal meeting bulgaria latvia annual conference regional workshop seminar patient advocate academics germany netherlands switzerland addition lead patient advocate deliver affordable cancer care high complete course individual income country eupati internet library therapeutic innovation patient group publish information work patient group online europe asia pacific emerge market region information support patient group work globally include detail funding receive voluntarily disclose funding support website detailed information gsk australia canada find websitesgsk corporate responsibility report behaviour human right gsk commit upholding recognise industry unique role play recognise support role convention effort improve health worldwide develop safe biological diversity cbd play provide universal declaration human effective treatment ailment affect patient framework conservation biological diversity right oecd guideline health strive medicine vaccine protect right country community product widely available possible run access share benefit arise read multinational enterprise business sustainable way approach cbd use biological core labour standard set material online safeguard place ensure human international labour organization right people take clinical research maintain high standard human right help ilo signatory protect include inform consent process good employee support relationship procedure protect patient privacy community near site ensure supplier global compact voluntary global especially careful protect right child contract run smoothly provide reliable supply standard human right labour involve clinical trial read highquality product protect reputation read approach clinical study human right statement online environment anticorruption respect promote right people note guide principle business human community near operation effort right endorse united nations human right believe government responsibility define improve access healthcare work help society council june believe represent valuable enforce legal framework human right broadly fulfil right health declaration contribution debate company accordance international law agreement human right state right operationalise human right responsibility business responsibilitie direct standard live adequate health wellbee appropriate diligence go forward consider control human right operation aim family include medical care good respond challenge set principle act responsibly sphere influence activity improve access healthcare support include employee supplier local community read health society broadly people community section early reportgsk corporate responsibility report behaviour human right activity embargo country approach human right stakeholder concern gsk business activity country subject trade embargo employment standard cover issue diversity equal opportunity burma myanmar north korea iran sudan employees health safety protect employee human right read people community syria share un belief people deny access medicine regime operate country aim provide medicine vaccine country party code conduct require supplier contractor business partner meet need wish purchase observe supplier gsk standard ethical standard human right environmental health safety eh sanction trading control apply country audits help identify potential breach human right clause read supply chain section behaviour nation longstanding commitment presence predate introduction measure trade embargo period government impose trade embargo ensure continuity gsk aim good relationship community site operate way infringe human right safeguard place ensure supply subject specific legal restriction community human right people take clinical research protect read demand product research practice section behaviour embargo country country business support commit uphold universal declaration human right influence human right operation effort improve ilo core standard observe local law society access healthcare support society broadly fulfil right health read health regulation read online publish position online include human right statement gsk convention biological diversity wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report planet content introduction waste carbon minimise use supply chain material source grow business operation environmental stewardship protect natural resource propellant environmental feature understanding need future governance impact product compliance water performance water operation external assurance commit minimise environmental click arrow impact section value chain lifecycle product set ambitious goal reduce carbon footprint water wastegsk corporate responsibility report planet introduction believe possible deliver target performance progress sustainable business growth performance target note reduce greenhouse gas emission facility protect resource need overall impact rise slightly carbon increase production volume increase impact future safeguarding reduction gsk overall travel inhaler use patient environment carbon footprint reduce water use waste send landfill value chain note site send zero waste water implement environmental sustainability develop product carbon footprint approach strategy entire value chain raw material reduction water individual product identify product disposal strategy focus carbon consumption note carbon hotspot measure reduce value chain dioxide emission contribute climate continue pilot takeback scheme inhaler change water use waste reduction environmental reduction gsk operational usa reduce waste greenhouse gas stewardship cover impact water consumption emission material product aim waste recycled waste pet plastic new ribena carbonneutral value chain reduction waste landfill bottle start deliver strategy operation receive rating performance score revise simple set measure enable reduction total waste disclosure carbon disclosure project assessment achieve goal diverse action generate operation need underway environmental stewardship office building certify gold leed need define mass efficiency new environmental rating system journey transparent pharmaceutical process publish report partner explore impact performance progress example participate proportion paper packaging climate change health carbon disclosure project cdp assessment sustainable source note score disclosure receive rating note performance achieve carbon trust target carbon water waste absolute target standard global certification second year mass efficiency paper packaging percentage target nnual performance available overall carbon footprint table show result main environmental water consumption reassess footprint value target datum follow page provide chain detailed datum download available online currently assess baseline paper packaging sgs verifiedgsk corporate responsibility report planet carbon longterm goal entire supply chain operation value chain carbon neutral understand carbon footprint supply chain reduce emission coequivalent straightforward use varied complex facility include energy material product gain deep insight production source main focus facility work closely key supplier carbon energy efficiency activity analysis examine impact value trust advisory consultancy develop product carbon see decrease coequivalent emission chain diagram estimate total carbon footprint approach individual offset increase manufacture footprint million tonne coequivalent product identify carbon hotspot measure production volume productionrelate coequivalent large contributor carbon footprint supply reduce initial result impact emission increase transport emission chain material input million tonne propellant vary widely product product read increase combined total reduction facility inhaler million tonne transport emission read continue progress sustainable operation million tonne source include engage ngo help shape combine heat power chp generation playing good progress develop plan source approach development network grow role decrease carbon emission area sustainability advocate procurement organisation instal chp unit bring total operating unit site manage impact value chain material operation distribution propellant use end life sgs verifiedgsk corporate responsibility report planet carbon chp help site irvine scotland reduce burn waste biomass fuel horlick propellant greenhouse gas ghg emission past year site make active ingredient horlick factory india use coal generate eliminate cfc gas product complete antibiotic augmentin energyintensive process power manufacturing process create substantially reduce inhaler emission aim help secure energy supply renewable approximately tonne coequivalent million tonne coequivalent source instal wind power turbine emission year approximately total million tonne today need operate early follow subject gsk operation replacement propellant powerful planning approval deliver annual site begin trial switch burn greenhouse gas time potent saving tonne coequivalent coal exclusively blend waste biomass increasingly supply dry powder inhaler approve million project convert waste heat use propellant patient child find renewable resource test number option plant singapore estimate annual saving difficult use continue improve standard rice husk pellet waste wood tonne coequivalent sawdust grain straw cotton straw ground nut propellantcontaine inhaler save energy high priority office shell trial prove successful ghg emission propellant increase building vaccine site saintefoy quebec plan blend waste biomass site primarily increase sale office building certify gold avoid tonne emission year currently investigate improvement include lee environmental rating system new long term aim waste biomass steam reduce propellant need inhaler pharmaceutical headquarters build philadelphia generation investment combine heat power trialle takeback scheme plan meet high environmental criterion technology generate electricity avoid propellant release read overleaf central fund available help develop specific waste biomass contribute local renewable energy energy reduction project economy create market waste previously past year support project limit value example propose pellet save approximately tonne supplier work microentrepreneur scheme equivalent detail energy carbon reduction produce income local people performance find datum download available online carbon disclosure project website reduction inhaler emission reduce million tonne coequivalent million tonne today sgs verifiedgsk corporate responsibility report planet feature understand impact product analyse carbon footprint value chain estimate total footprint million tonne highlight main contributor emission supply chain propellant release use inhaler product build understanding need know impact individual product sgs verifiedgsk corporate responsibility report planet feature understand impact product develop product carbon footprint approach take inhaler ventolin carbon footprint initial result vary widely collect inhaler avoid waste greenhouse product product demonstrate contrast gas emission extend trial carbon footprint propellantbase inhal takeback scheme work close ventolin inhaler advair diskus dry powder inhaler pharmacist encourage patient return carbon footprint respiratory product inhaler collect new pharmacist send inhaler gsk recycle partner carbon footprint ventolin show need separate plastic remanufacture capture focus reduce release propellant hfa remain aerosol propellant trial begin atmosphere responsible usa pharmacie city material footprint coequivalent device operation explore range option include reduce extend initial trial packaging propellant need capture propellant operative supermarket chain pharmacy transport lose manufacturing recycling device sixmonth trial estimate purchase inhaler propellant use investigate alternative propellant return save propellant potent analysis advair diskus dry powder inhaler greenhouse gas avoid equivalent tonne advair diskus carbon footprint footprint show need focus plastic emission plan expand programme device energy impact product use operation account need understand well environmental product footprint device coequivalent impact product patient device shortterm improvement priority consumer commission study focus option recycle plastic device usephase carbon footprint product improve energy efficiency operation base estimate usephase emission million metric tonne coequivalent material exclude impact propellant horlick operation toothpaste product packaging transport learn emission product use dependent type product example prescription medicine large use phase impact derive paper bag label attach medicine dispense pharmacy sgs verifiedgsk corporate responsibility report planet water waste water water operation recycle waste understanding impact business value chain continue sitelevel action improve water use innovation lead waste pet water complex unlike carbon emission reduction plastic bottle ribena previously impact global water use local global develop water kaizen rapid improvement process waste contractor dispose approximately tonne impact need account user identify efficient way use water pilot pet packaging tray deliver component watershe seasonality water quality approach worthe maidenhead site site ware evreux france southeast england identify potential saving material recycle create new ribena bottle gsk active ceo water mandate opportunity save approximately tonne cosponsor work develop disclosure guideline implement significant investment coequivalent emission year guideline help company measure example include fitting aerator tap decommission communicate performance effectively hope redundant equipment optimise service water flow ultimately lead water footprint approach similar fitting trigger gun water hose site greenhouse gas protocol investigate opportunity identify kaizen perform highlevel analysis entire process high grade waste water value chain quantify overall water consumption plant instead identify area risk concern help additional potable water understand water impact well identify waste opportunity reduce overall impact initial result suggest great contribution water continue progress reduce impact footprint come use water associate waste total waste hazardous non raw material supply chain hazardous fall volume landfill work reduce spread waterborne total site send zero waste disease landfill read innovation drive waste way example employee xochimilco mexico find way use panel refrigerate vaccine shipping packaging insulation material construction industry reuse material avoid tonne waste year previously pay send landfill sgs verifiedgsk corporate responsibility report planet waste example reduce packaging waste drive sustainability external engagement include convert glass plastic bottle horlick reduce packaging material consumer healthcare continue collaboration gsksingapore pharmaceutical industry copublishe product convert blister pack film partnership green sustainable manufacturing key green engineering research area metric wrap nasal spray flixotide estimate programme gsk propose industry green chemistry measure avoid tonne problem sustainability study academic publish report accenture equivalent year community prepare research proposal solve university oxfords smith school enterprise problem round proposal award revise green packaging guide help environment explore impact climate change symposium hold designer avoid waste choose sustainable health believe important area award grant singaporean researcher option guide include sustainability assessment tool little understand research suggest different area sustainable manufacturing amounting cover energy water use carbon benefit temperature change million footprint packaging material transport carbon small malarial zone parts africa tracker collect datum monitor progress work industry partner overall impact negative climate change create million sustainable chemistry partnership threaten life wellbee billion people minimise use material source academia european innovative extreme weather directly increase disease continue work increase efficiency medicine initiative start work death indirectly result region use material new pharmaceutical product gsk american chemical society struggle sufficient food clean water sanitation average mass efficiency new primary process green chemistry institute pharmaceutical roundtable world poor people likely affect transfer manufacture collaborate pharmaceutical research starting point welcome compare target company green chemistry engineering opportunity work develop well believe increase mass efficiency understand pharmaceutical industry product transfer manufacturing need respond measure solvent recovery grant create new group work second generation product development improve sustainability profile manufacturing portfolio project product lifecycle singaporean creation sustainable find online research area org process re dev researcher area chemistry partnership metric org process re dev sustainable manufacturing imi report cimate change health framing issue available publication section website sgs verifiedgsk corporate responsibility report planet stewardship governance environmental stewardship environmental governance ceo ehs sustainability awards key tool engage employee refresh award main theme environmental strategy progress internal governance reflect new strategy aspiration particular carbon water waste work broad environmental sustainability internal recognise project show demonstrable benefit environmental issue include eliminate use external engagement business strategic area year receive material concern material concern responsibility environmental sustainability rest application chemical scientific evidence show probable corporate executive team cet formally environmental sustainability category entry come longterm effect human environment review performance year read country area carbon water exist potential future corporate responsibility committee review waste general environmental sustainability legislation restrict use progress example award include programme energy total tonne material development reduction operation improve manufacturing compare tonne new sustainability steering team meet quarterly route new product water reduction initiative refrigerant cfcs ozone depleting consist senior leader site australia read substance use site miss business bring commercial perspective winner eh category environmental debate engage local operating target eliminate cfc use company issue team responsible external stakeholder panel provide advice reduce mass cfc compare shape environmental strategy integrate environmental sustainability environment mainly cfc replacement continue business strategy relevant health safety matter meet pursue stretching integrate environmental long meet current form currently restate policy pharmaceutical sustainability specific business unit goal review approach aim achieve deep environment reflect recent scientific grow environmental sustainability practitioner engagement diverse global group advance current practice position remain base help employee involve stakeholder line strategy work compound expect cause creation network site champion value chain human health environmental impact environmental sustainability key continue build deep scientific understanding environment health safety sustainability ehss issue order address concern evaluate policy cet approve cover pharmaceutical effluent fundamental approach risk management manufacturing facility support voluntary ambition sustainability commitment responsible programme deal safe disposal transparency unused medicine source pharmaceutical environment sgs verifiedgsk corporate responsibility report planet compliance remain vigilant stay internal audit compliance environmental audit operation contract manufacturer key supplier base assessment system manage law regulation significant risk impact compliance legislation performance environment health safety incur environmental fine sustainability ehss standard large malaysian ringgit members ehss audit team certify iso approximately kuala lumpur insufficient lead auditor gsk audit space store schedule waste prior collect assurance function provide independent audit destruction assurance capability separate management organisation function use riskbase audit process fine singaporean dollar approximately site singapore follow professional practice framework read online potential mosquito breeding canvas sheet leave need audit determine modelling key outdoors collect rain water risk indicator trend previous audit finding publish position online include event follow corrective action ehss audit strategy prompt audits climate change site world include review satisfied requirement impact climate change health environmental management system addition gsk advise responsible party team carry theme audit management enetically modify microorganism ehs approximately environmental remediation site hazardous waste number facility nanomaterial appear national priority list create hazardous chemical management general performance relate management comprehensive environmental response compensation environmental risk find manage gsk reach regulation liability act superfund gsk convention biological diversity read ehs audits key supplier supply instance gsk involvement related waste chain section pharmaceutical environment disposal site gsk responsible party gsk potential liability vary greatly site ozone depletion metereddose inhaler asthma site gsk routinely accrue fund ensure zone deplete substance plant equipment meet obligation wwwgskcomreportsandpublicationspolicie sgs verifiedgsk corporate responsibility report planet performance progress carbon performance datum summary environmental sustainability strategy impact operation fall mainly drive note change work longterm aim investment project support climate change carbon thousand tonne coequivalent annum programme close number facility carbon neutral value chain balanced acquisition growth carbon footprint note overall impact operation transport inhaler climate change impact use rise slightly increase production volume raw material note increase impact travel inhaler use patient operation operational energy detailed information performance source find datum download available online transport product transport climate change impact operation transport employee air travel inhaler use sale force vehicle million tonne equivalent total inhaler use patient target water million cubic metre water use operation waste thousand tonne use inhaler patient operation energy total operational waste generate travel transport total operational waste landfill source source include waste treatmentrelate release production nonhazardous waste generate release inhaler production loss refrigerant loss travel transport coequivalent exclude methane emission hazardous waste generate note value restate previous report estimate datum december include actual datum available time report publication reassess carbon footprint accross value chain annual performance available sgs verifiedgsk corporate responsibility report planet performance water waste destination waste net water consumption fall range total waste generate fall slightly drive non water save recycle water use initiative hazardous waste reduction achieve waste reusedrecycle business site closure reduction reduction project change production incineration offset business growth particularly big progress zero landfill programme energy recovery consumer healthcare manufacturing vaccine site roll business majority waste incineration expansion detailed information find reuse recycle onsite follow incineration energy recovery datum download available online recycled waste solvent recover onsite landfill detailed information find datum download available online net water consumption operation total waste generate mass efficiency mass efficiency million cubic metre million kilogram total target target hazardous nonhazardous exclude nonroutine waste construction demolition stage stage stage stage stage range average waste landfill chart show average range mass efficiency process million kilogram development stage pipeline process transfer manufacturing period average mass efficiency target mass efficiency primary process transfer average stage refer transfer manufacturing weight average sgs verifiedgsk corporate responsibility report planet external assurance basis report short form external assurance opinion external assurance assurance statement basis methodology describe verification work perform satisfied datum energy emission datum collect collection reporting process place robust pharmaceutical consumer healthcare sgs united kingdom ltds short form report manufacture site vaccine site pharmaceuticals environment health safety datum environmental health safety datum contain glaxosmithkline corporate responsibility report gsk corporate responsibility report consumer healthcare site headquarters reliable provide fair balanced representation building office distribution centre water sgs united kingdom ltd commission gsk environmental health safety activity nonhazardous waste datum collect glaxosmithkline gsk conduct independent assurance team opinion report manufacture vaccine operation major assurance environmental health safety datum reporting organisation stakeholder office location base materiality assessment corporate responsibility report collect hazardous waste wastewater data assurance statement available online scope assurance base sgs sustainability office site manufacture consumer healthcare report assurance methodology include sign nutritional product volatile organic compound environmental datum contain planet section behalf sgs united kingdom ltd vocs report site manufacture report health safety datum contain jan saunder pharmaceutical contain pilot plant use people community section report system service certification greenhouse gas protocol calculation detailed datum table sgs logo find united kingdom february emission energy use propellant relevant gsk report highlight wwwsgscom refrigerant use country factor electricity datum include assurance scope publish international energy agency gsk response assurance scope assurance select base sixth year sgs review datum pleased sgss finding good practice material issue identify gsk include environment section corporate responsibility recognition robust data collection analysis environment health safety key performance report independent view process report committed continue improve indicator kpi subject corporate level improvement valuable adopt suggestion ultimate goal continue provision accurate datum target assurance include interview document year improve process public website datum corporate review gsk facility london irvine site select review gsk slough singapore poznan poland research responsibility report site improve management environmental health safety business site visit special focus triangle park usa biopharm usa programme continue work site contributor environmental site improve data submission include provide emission previous year site implement comment explanation trend complete innovative ehs project relatively new site timely fashion previously visit sgs datum verification site difficulty submit datum timely manner response specific area sgs assurance statement find online sgs verifiedgsk corporate responsibility report governance management governance management boardlevel corporate committee member sir christopher principles gent chair stephanie burn james murdoch responsibility committee daniel podolsky go forward james murdoch principle underpin value nonexecutive director provide decide step board year agm identify key responsibility issue provide offer reelection guidance standard gsk commit highlevel guidance approach committee review progress meeting ceo member corporate executive team corporate responsibility commitment cet accountable responsible management review policy progress business participate committee meeting principle map key theme important responsible committee meet time year receiving report sustainable business growth member cet senior manager review health ensure progress meet principles committee report finding board access medicine read committee report research innovation governance section annual report online augment gsk engagement stakeholder opinion people community march sophia tickell appoint employment practice independent external adviser committee community investment sophia cofounder director meteo direct pharma future series aim align well societal shareholder value behaviour sit expert review committee access standard ethical conduct medicine foundation member european product customer healthcare innovation leadership network sophia attend meeting committee provide leadership advocacy independent advice guidance corporate human right responsibility matter chairman ceo engagement stakeholder mid avoid conflict interest new role sophia decide planet retire adviser committee caring environment detail principle available onlinegsk corporate responsibility report governance management approach cover diverse range issue audit assurance external assurance believe manage assess aspect responsibility performance environment health safety reporting business function internal external assurance process externally assure sgs independent external assurer audit assurance department responsibility relevant subject expert work assurance process include verification key independently assess sample basis process environment health safety datum site visit control place comply law regulation telephone call ehs professional review crossfunctional team company standard gsk audits focus system process collect collate analyse representative key business area oversee key business risk area gsk interpret datum read assurance statement development implementation communication function responsibility independently assess policy include responsibility element adequacy effectiveness management gsk member team senior manager previously assure section report significant risk area report outcome audit direct access corporate executive team year process review risk committee line agree assurance plan small central team coordinate policy approach assurance section development report specifically relate issue identify audit team recommend report communicate responsible investor improvement gsk manager develop action plan risk management stakeholder address cause noncompliance address gap internal control department track plan risk oversight compliance council rocc completion report result senior coordinate management significant business management audit risk committee risk oversee internal control ensure compliance review key business issue antibribery corruption abac programme applicable law regulation gsk policy strategic challenge build value standard form nonfinancial reputational risk include recently introduce future strategy group comprehensive practical approach compliance core risk management process review approach key business issue complex risk area programme oversee significant risk include nonfinancial risk address strategic challenge lead abac team provide advisory support risk management process describe ceos office provide valuable opportunity high routine audits risk annual report potential employee work closely corporate supplement traditional audit programme strategic executive team group work bring business growth achieve risk evaluation sre conduct partnership senior manager expert business acquisition diligence process place business evaluate area gsk risk appetite design allow innovative thinking design identify risk pose mitigation strategy unclear undefined base development new approach fsg new business acquisition include ethical social emerge nature risk risk maturity convene include focus area environmental risk level gsk response approach malaria access healthcare animal research read approach read assurance internal audit risk progress area health management governance section research practice section early report annual reportgsk corporate responsibility report governance management value corporate responsibility value corporate responsibility responsible business benefit gsk facilitate great access market ability increase access make product society operate help operate efficiently influence healthcare policy improve accessible affordable gain trust stakeholder create product relationship regulator healthcare payer invest people community patient healthcare payer need working government increase access operate foster right condition growth business resolve healthcare challenge particularly important ensure ethical standard research development operate responsibly fully integrate principle help anticipate prepare legislative change sale marketing business strategy long term remain competitive environmental impact particularly relate support licence operate ability helps maintain support intellectual property climate change improve people live product system find innovative way increase access medicine number factor influence assessment build trust gsk product include business strategy risk management reduce cost increase environmental enhance ability attract retain motivate process stakeholder interest include investor efficiency efficient use resource talented people increasingly important few feedback change business operation young people major market choose science consider follow responsibility issue example type product produce base career material gsk location operate exist propose legislation public opinion support constructive engagement stakeholder contribution health wellbeing help prevent avoidable conflict research development manufacture identify innovative approach benefit gsk sale medicine vaccine consumer wide society healthcare product annual report read business strategy performance find lie loe ntt detail corporate governance risk management annual report shareholder annual report onlinegsk corporate responsibility report governance management stakeholder engagement stakeholder engagement dialogue stakeholder example engage enable touch healthcare professional hcp sale representative meeting view opinion society interaction clinical study conference operate help identify engagement professional organisation important issue shape patient meeting gsk scientist patient response interest focus patient programme shareholder wide society work patient advocacy group market research understand patient need regular engagement mean well inform government regulator public policy work emerge current issue change expectation provide opportunity voice approach advocacy key issue access healthcare responsibility issue obtain important feedback build investor meeting investor participation key sustainability index trust discussion take place normal course business provide training help manager participation carbon disclosure project market communicate local stakeholder employee regular employee survey approach responsible business transparency way engage stakeholder consultation employee representative change business outline report local community interaction site level range issue community investment programme multilateral agency engagement access healthcare public health initiative nongovernmental organisation engagement issue relate access medicine community investment public policy animal welfare scientific community participation academic collaboration participation scientific debate supplier global regional supplier review meeting meeting diverse supplier peer company pharmaceutical industry organisation meeting joint project pharmaceutical supply chain initiativegsk corporate responsibility report governance management performance gsk receive recognition awards gsk rank access medicine index second time june area business index ranking review assess rdbased pharmaceutical company seven generic company performance seven criterion provide summary management influence pricing patenting capability philanthropy performance key investor focus gsk rank high seven category index award gsk continued member dow jones sustainability index cover sustainable company sector gsk award bronze class distinction survey publish gsk include ftsegood index benchmark company corporate responsibility parameter include environmental sustainability stakeholder relationship human right supply chain labour standard business ethic gsk rate healthcare sector new ftsegood esg rating score maximum assessment score company approach performance base publicly available information carbon disclosure project cdp leadership index rank gsk global company score disclosure rating performance thomson reuters extel sustainability sri survey gsk lead quote company sustainability investors award base vote european fund manager investment banksgsk corporate responsibility report cover leave right photo credit early stage research new biopharmaceutical take place large chairman george brooks centre stevenage people worldwide work ceo tom whipps search new medicine vaccine consumer healthcare health chris martin leave tom whipp right products george brooks focus patient george brook approach malaria tom whipps mother child wait outside malaria clinic tanzania mobile phone tackle counterfeit nigeria tom whipps child seven country subsaharan africa take approach neglect tropical disease ntd marcus perkin ongoing largescale trial evaluate malaria vaccine candidate rtss measure impact phase programme chris martin tom whipps treatment child hivaid chris martin vijana tunaweza newala jennifer mcclearysillsicrw gsk official laboratory service provider london people communities david tett leave george brooks right olympic paralympic games school outreach programme respond japanese earthquake photothe yomiuri shimbun scientist sport aim inspire young people science masataka morita demonstrate role science play games david tett ring science london olympic paralympic games david tett carbon footprint come propellant release impact award stamp production use inhaler product takeback scheme trialle behaviour tom whipps leave george brooks right recycle return inhaler plastic hang way incentivise sale team usa sean locke manufacture propellant nonmedical use ian enness getty image cover planet thampapon otavornrf leave impress photography right visual inspection vials zhangjiang site china quality burn waste biomass fuel horlick thampapon otavornrf understanding impact product ian enness heart activity support discovery supply understanding impact product impress photography distribution product patient consumer tom whipps recycling waste george brooks man lymphatic filariasis know elephantiasis care leg limit effect disable disease gsk donate albendazole treatment world health organization lead effort eliminate marcus perkin red cross doctor help victim japanese disaster gsk donate product worth million million cash japanese red cross gsk japan employee volunteer deliver food blanket aid affected area photothe yomiuri shimbun masataka morita gsk phase programme run partnership ngo work improve water quality educate community importance handwash reduce spread diarrhoearelate disease gettyclaudia dewald print amadeus offset recycle paper fsc certification pulp deinked postconsumer waste elemental chlorine free ecf manufacturing mill hold iso ecolabel certificate environmental management mill zero landfill extremely low carbon emission lead wwf approve paper environmentally sustainable uncoated recycle paperwwwgskcom download pdfs report website annual report corporate responsibility report head office register office glaxosmithkline plc great west road brentford middlesex united kingdom tel register number wwwgskcom